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ABSTRACT 
This thesis describes the assessment of depression and anxiety by 
questionnaire and visual analogue scale in patients with irritable bowel 
syndrome (IBS). It examines the relationship between such assessments and 
self- reported symptoms before and after a placebo controlled, double -blind 
trial of fibre supplementation in 49 IBS patients, and finds that a high 
depression score at outset may be a predictor of continuing symptoms 
regardless of treatment. The treatment itself was no better than placebo, 
though there was a substantial 'placebo' effect. 
I consider the use of putative biochemical markers of 'stress' in such patients, 
but find that neither salivary IgA nor urinary metanephrine correlate well with 
symptoms, symptom response, or psychometric assessment scores. Platelet 
serotonin levels did not distinguish IBS subjects from those with other chronic 
gastrointestinal complaints. It seems unlikely that any of these parameters will 
be helpful in routine diagnosis or management of IBS. 
A second cohort of IBS subjects was studied five years after initial diagnosis, 
using similar psychometric assessments. The chronic nature of the disorder 
was confirmed. The results suggest that anxiety levels might be an important 
influence on the longer -term maintenance of the symptom complex. 
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Finally the thesis examines aspects of the general practitioner consulting 
behaviour of a group of IBS patients. Such behaviour seems relatively stable 
over the longer term although there was a very high prevalence of diagnoses 
of depression or anxiety, both before the IBS diagnosis and during the five 
years to review. 
The studies are considered to support a holistic approach to IBS; its 
pathogenesis, management, and natural history. The symptom complex is 
forged by the action of several factors, notably psychological, physical and 
circumstantial (life events). The behavioural and emotional elements of the 
symptom complex are best considered as one product, and the doctor - 
patient relationship plays an important modulating role. There is some 
evidence that depressed mood may be more important in determining short 
term responses, such as consulting behaviour, and anxiety in maintaining the 
perception of 'symptoms' in the longer term. Simple assessment of 
depression and anxiety, perhaps by 'user friendly' visual analogue scales, 
might usefully be incorporated in the routine assessment of IBS patients. 
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The symptom complex now termed irritable bowel syndrome (IBS) has been 
recognised for many years. Powell (1820) provided the first written description 
of the syndrome ; 'occasional pain in the intestines and derangement of their 
powers of digestion with flatulence and a sense of suffocation'. Around the 
turn of the century studies of 'membranous enteritis' and 'membranous colitis' 
were reported by Da Costa (1871) and White (1905) respectively. Allbutt 
(1884) described 139 cases of 'neurosis of the viscera'. Hawkins (1906) noted 
that such conditions had no organic cause and were not helped by surgery. 
Bockus et al (1928) considered that many patients with 'neurogenic mucous 
colitis' displayed evidence of psychoneurosis. 
Peters and Bargen (1944) coined the name irritable bowel syndrome and 
commented that the increased incidence of IBS in the war years might be 
evidence of an association with stress. In subsequent years Almy (1951) again 
noted the frequency of neurotic traits, and developed experimental models 
aimed at testing the hypothesis of a link between stress and altered motility 
of the GI tract. Chaudhary and Truelove (1962) further described the 
syndrome emphasising the importance of psychological factors and the 
chronic nature of the condition. 
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IBS is a common diagnosis in gastrointestinal practice. Ferguson et al (1977) 
reported that in almost fifty per cent of patients referred to a gastrointestinal 
outpatient clinic the diagnosis was of IBS. In 888 of 2000 consecutive referrals 
to a gastrointestinal clinic the diagnosis was of functional disorder, of which 
IBS accounted for half (Harvey et al 1983). Switz (1976) confirmed that 
functional disorder was the most frequent diagnosis in patients referred to 
gastroenterologists in the developed world. Despite the frequency with which 
it is encountered, IBS remains an enigma, its aetiology unestablished, its 
treatment often difficult and contentious. 
Insight into IBS has been greatly disadvantaged by poor definition of the 
syndrome and by a dualistic conflict over its likely aetiology. The symptom 
complex is considered by some to be the result of gastrointestinal 
dysfunction, perhaps dysmotility, though the precise nature of the organic 
disorder is not yet established (Grant Thompson 1984a, Kumar and Wingate 
1985). To others IBS is a manifestation of psychiatric disturbance (Hislop 
1971). The medical model of illness, to which most physicians owe historical 
(if not intellectual) allegiance, does not easily accomodate both these 
positions. Yet it has long been recognised that complaints and symptoms do 
not always have an explanation in physical disorder (Cabot 1907). Such 
symptoms are said to arise from 'functional disorder' and are frequently 
encountered in medical practice. 
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The concept of 'functional disorder' is itself poorly defined and it can be 
argued that the availability of this diagnostic label has further hindered 
understanding of IBS. The absence of organic disease does not imply that the 
symptoms have their origin in psychiatric illness (Bridges and Goldberg 1984); 
but neither does the absence of psychiatric illness or 'symptoms' imply 
psychological normality. 
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The IBS Symptom Complex 
The 'symptom complex' and its assessment are the starting points common 
to the patient and to the consulted physician. For the patient the assessment 
fires the process by which the experience may give rise to symptoms, and 
to seeking medical attention. For the physician the assessment of 
gastrointestinal tract function is central to the diagnostic process instigated 
by the patients attendance. For both participants the eventual formulation will 
carry significant implications for future behaviour. 
The relationship between reported symptoms and objective measures of 
gastrointestinal function is not well established. Eastwood et al (1984) 
confirmed a relationship between constipation and increased enteric transit 
time, a finding demonstrated by Cann et al (1983), who also described a 
reduction in whole gut transit time associated with diarrhoea. An altered small 
bowel motility pattern was said to coincide with symptoms (Kellow and Phillips 
1987). However Oettle and Heaton (1987) found poor correlations between 
colonic symptoms, intestinal transit time, and stool weight over a 28 day 
period. Hillman et al (1982) found no relation between reported symptoms 
and objective measures of diarrhoea and constipation. Whitehead et al (1980) 
found no correlation between changes in myoelectric activity induced by 
rectosigmoid distension and the severity of symptoms. Despite this variable 
correlation between symptoms and enteric events, in the absence of any 
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distinctive biochemical or physiological characteristic, the definition and 
diagnosis of IBS must be based on reported symptoms. 
The symptom complex is dominated by abdominal pain and a change in 
bowel habit. Clinical studies have focussed on differentiating IBS from organic 
disease and on classifications of the syndrome according to symptom 
patterns. IBS is frequently subdivided into constipated, diarrhoeic, or 
alternating types. Such a classification is greatly limited by the wide variation 
in interpretation of bowel habit and its description, and by the variability of 
bowel habit disturbance in individual patients across time. Some still regard 
the diagnosis as one of exclusion (Sammons and Karoly 1987) but there is 
now general agreement that the diagnostic process can be a positive one. 
This positive diagnostic process has been advanced by Manning et al (1978) 
who define the gastrointestinal symptomatology in IBS. In discriminating IBS 
from organic disease the symptoms with greatest power are : 
1. abdominal distension (as evidenced by tight clothing or visible 
appearance). 
2. pain relief with bowel action. 
3. more frequent stools with onset of pain. 
4. looser stools with the onset of pain. 
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At least two of these symptoms are present in 91 per cent of patients with 
IBS but in 30 per cent of those with organic disease. In only seven per cent 
of IBS patients were none of these symptoms reported : 52 per cent of those 
with organic disease denied all of these symptoms. 
Kruis et al (1984) proposed a diagnostic score based on an analysis of 479 
patients. Using the weighted score at a sensitivity of 83 per cent, the 
specificity was 97 per cent. Unlike Mannings' system, the Kruis scoring 
system incorporates laboratory results as well as reported symptoms. 
While such systems may distinguish IBS from organic gastrointestinal disease 
in clinic patients, the experience of a unique constellation of gastrointestinal 
events does not distinguish patients with IBS from 'normal' subjects in 
community surveys of bowel function. Up to 35 per cent of 'normal' people 
report gastrointestinal experiences indistinguishable from those of IBS 
sufferers in surveys of the general population (Thompson and Heaton 1980, 
Drossman et al 1982). Almost half the 'normal' population reported a 
significant 'bowel' dysfunction, defined as : 
1. alternating bowel habit more than 25 per cent of time. 
2. at least six episodes of abdominal pain in the preceding year with three 
or more of the following characteristics ; relief by defaecation, loose 
stools with the pain, more frequent stools with the pain, abdominal 
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distension, mucus in the stool, or incomplete evacuation. 
3. constipation ; straining at stool, or less than two stools per week. 
4. diarrhoea ; loose or watery stools for more than 25 per cent of the 
time, or more than 21 stools per week. 
These are precisely the components of the IBS symptom complex ; but a 
minority of people with this gastrointestinal experience profile become IBS 
patients (Thompson and Heaton 1980, Whitehead et al 1982). It is recognised 
that increased symptom severity increases the likelihood of seeking medical 
attention in some circumstances, notably where anxiety or depression is the 
dominant complaint (Ingham and Miller 1983). However there is little to 
support the proposition that symptom severity is the factor which 
distinguishes IBS symptom reporters (patients) from IBS suffering non - 
reporters. 
Coincident symptoms might be a factor in determining that the experience of 
the IBS gastrointestinal symptom complex precipitates seeking medical 
attention. Non -gastrointestinal symptoms are common in IBS (Whorwell et al 
1987). Maxton et al (1989) confirmed a high prevalence of non -colonic 
symptoms in 100 IBS patients. Almost half the patients rated such a non - 
colonic symptom as the most troublesome for them. It is not clear whether 
IBS 'non -patients' share this additional, non -gastrointestinal symptom profile. 
It is characterised by complaints such as tiredness, lethargy, and headache, 
18 
as well as genitourinary symptoms such as urinary frequency and 
dyspareunia. 
IBS therefore seems to be a dimensional disorder, there being a continuum 
of experience with no clear line of delineation between patient and non - 
patient. Although the dominant complaints are most frequently gastrointestinal, 
patients often acknowledge troublesome non -gastrointestinal symptoms. It 
seems possible to reach a diagnosis positively by analysis of the symptom 
complex and simple clinical examination. 
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Illness Behaviour 
The transition from experience to symptom, and the reasons for seeking 
medical attention, are central themes of illness behaviour theory. This shifts 
the emphasis from the standpoint of the traditional medical model - what is 
wrong ? (a structural approach), to an approach which rather asks - why is 
this individual behaving in this way at this time ? (a functional approach). 
It has been argued that those who seek medical advice are distinguished 
from non -seekers with similar experiences by a disturbed sense of well- being. 
Where an individual considers that a threat to well -being exists, the response 
is generally to bring into play strategies which serve to minimise the disruption 
and distress. Such strategies may be behavioural and /or emotional. 
Consulting the doctor can be seen as one such response or 'coping 
strategy'. 
A vast literature attests that cultural and psychosocial factors influence help - 
seeking (or consulting) behaviour. Behavioural studies have shown ethnicity, 
family structure, personal attitudes and values, informal social influences, and 
access to care, to be among the most powerful of such influences. However 
field studies often find much less vigorous associations between such factors 
and consultations. Mechanic (1979) considers why this apparent conflict might 
arise in methodological and conceptual differences, but these limitations must 
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be considered when interpreting such studies. 
Andersen and coworkers (Andersen and Newman 1973) have described a 
model which seeks to explain the great variability in consulting behaviour. 
They propose that the factors which modulate consulting can be divided into 
three sets. 
Predisposing factors are those which exist before the onset of 
the 'illness'. Those most often cited are demographic (age, sex, 
and marital state), social (class, educational attainment, 
occupation), and attitudes and beliefs. The contradictory 
literature is well exemplified here - social class and educational 
level have been found to be associated (Ingham and Miller 
1983) and not associated (Wolinsky 1978) with the likelihood of 
consulting. However there is a concensus that women consult 
more frequently than men but that this reflects need factors as 
well as an increased disposition to seek reassurance from 
doctors (Briscoe 1987). Consultation rates increase with age 
from the late teens but this may reflect the increased likelihood 
of disease states (circumstances which provoke the response) 
rather than changes in predisposition. This distinction may be 
equally important for other factors. 
21 
Enabling factors are those concerned with the availablity of 
services. This set includes cost (and its relation to income) and 
geographical distance. Clearly many of the social predisposing 
factors will impinge here. 
Need or illness factors are those which concern the immediate 
cause of the putative consultation. Symptom severity is an 
important determinant of consulting behaviour (Ingham and 
Miller 1983), as is symptom chronicity. But symptom severity 
does not necessarily correlate with the degree of distress 
engendered, and perceived seriousness is a further influence on 
help- seeking behaviour (Hulka 1972). 
Perception and evaluation are clearly delineated in Andersons' 
conceptual framework. In other work evaluation is subdivided into 
interpretation and attribution and still others use 'evaluated illness' 
synonomously with 'diagnosed illness' (Banks et al 1975). 
Psychiatric morbidity is well established as an important 
determinant of consultation (Barsky et al 1986, Williams et al 
1986, Vasquez -Barquero et al 1990). 
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In the context of irritable bowel syndrome the factors which are preeminent 
influences on the perception, interpretation and attribution of the symptoms, 
and on the development of the consulting response, can usefully be 
considered in 4 domains which overlie the predisposing, enabling, and need 
sets: 
1. The nature of the potentially destabilising event. 
2. The psychological profile of the individual. 
3. Previous experience of this and other events. 
4. The circumstances in which this interaction is occurring. 
Each of these domains is now discussed in relation to the aetiology and 
natural history of IBS. 
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Illness Behaviour 
The nature of the potentially destabilising event 
Intestinal dysmotility 
Gut spasm is an attractively simple explanation for the symptoms in IBS, 
particularly abdominal pain. It has long been recognised that in IBS patients 
symptoms can be provoked by changes in intraluminal pressures in the small 
intestine or colon produced by inflation of balloons (Holdstock et al 1969). 
Ritchie (1973) demonstrated that rectosigmoid distension to 60m1 at 35cm 
from the anal margin caused pain in 55 per cent of IBS patients but in only 
six per cent of controls. Distension in the colon had a similar profile of 
response (Ritchie 1973, Whitehead et al 1980). Swarbrick et al (1980) and 
Moriaty and Dawson (1982) showed that distension of other sites, including 
the oesophagus and the small intestine, caused pain. 
Abdominal pain is such a dominant symptom in IBS that it has been the 
subject of much study. The site of the pain is extremely variable, occurring in 
many positions in the abdomen (Chaudhary and Truelove 1962), and at extra - 
abdominal sites. Pain has been reported in the chest, lumbar spine, sacroiliac 
joints, and thighs (Holdstock et al 1969). Frequently many sites are involved. 
Pain may be continuous or colicky, or both (Chaudhary and Truelove 1962). 
With enteric distension the pain tends to be felt in the midline in normal 
controls, but in IBS patients it can be located anywhere in the abdomen 
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(Swarbrick et al 1980, Moriaty and Dawson 1982). The site of the distension 
does not predict the site of the pain. The distension -provoked pain is similar 
in character and position to their usual pain in 50 per cent of IBS patients 
(Swarbrick et al 1980). 
In one study distension pain threshholds were lower in IBS patients than 
controls (Ritchie 1973). Colonic hyperalgesia, in which there is greater 
perception of noxious colonic stimuli, was a suggested explanation. Latimer 
et al (1979) could not reproduce the findings of reduced pain threshhold to 
colonic distension in IBS patients, reporting a linear correlation between pain 
and distension in IBS subjects, in normal controls, and in psychologically 
disturbed patients in whom gastrointestinal symptoms were not a feature. 
Latimer et al criticised the controls used by Ritchie, many of whom were 
constipated. Cook et al (1987b) reported that IBS patients had greater pain 
tolerance to electrocutaneous stimulation than normal subjects. Interestingly 
a group of Crohns disease patients also had higher pain tolerance than the 
controls. This argues against the suggestion that IBS patients might 
overperceive abdominal experience or magnify the pain ; 'somatic 
amplification' (Barsky 1979). 
Nor is there evidence to suggest that IBS patients are habitually subject to 
unusually great distension as a consequence of increased enteric gas 
production. Lasser et al (1975) found similar rates of production and 
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composition in 18 IBS and 10 control subjects. This is not to exclude a 
possible role for enteric gas - clearly its' production and composition, to a 
large extent dependent on diet, may have profound influences on enteric 
motility patterns. 
Colonic motility. 
Colonic motility studies are beset with difficulties of methodology and 
terminology. There are three main types of mechanical activity (contractions): 
1. segmental contractions 
2. propulsive contractions 
3. mass movements 
Colonic contractions are brought about by electrical activity within the smooth 
muscle of the bowel wall. There are two electrical wave rhythms in the colon: 
i. 3 cycle / minute slow wave activity, intrinsic and intermittent. 
ii. 6 -12 cycle / minute activity. 
Contractions occur only if the action potential discharge coincides with slow 
wave activity. Although no single characteristic pattern of myoelectric activity 
unique to IBS has been identified, several abnormalities occur with greater 
frequency or to a greater degree in IBS subjects than in controls : 
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(1) Alterations in slow wave 3 cycle / min activity. 
Chaudhary and Truelove (1961) reported that colonic motility was increased 
in IBS patients with constipation though other studies failed to confirm this 
(Snape et al 1977). Trotman and Misiewicz (1988) found sigmoid hypomotility. 
Whitehead et al (1980) described gastrointestinal tract motility in 28 IBS 
patients. The colon and small intestine seemed hyperactive in IBS, but not 
under resting conditions. In the colon slow contractions of at least 15s 
duration occurring irregularly were more frequent in IBS (both diarrhoeic and 
costive types). Fast contractions were more common in diarrhoeic type only. 
Sarna et al (1982) referred to electrical control activity (ECA), which is 
equivalent to slow wave activity, as the basic myogenic phenomenon. ECA 
modulates electrical response activity (DERA) which are spike bursts 
responsible for rhythmic contractions. In the colon ECA is irregular. They 
failed to confirm increased ECA (3 cycle / min activity) in IBS patients. Welgan 
et al (1985) likewise found no difference in 2 -4 cycle / min slow wave activity. 
Frexinos et al (1987) found reduced or absent short spike bursts (SSB) 
(equivalent to the DERA of Sarna). He also reported an increase in the total 
number of migrating long spike bursts (MLSB) after eating in painless IBS of 
diarrhoeic type. Bueno et al (1980) described three groups of colonic motor 
disturbance including SSB of high amplitude which were said to occur with 
bouts of pain. 
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(2) Increased contractions at 3 cycle / min (Sullivan et al 1978). 
The abnormally high incidence of slow waves (3 cycle / min ), possibly 
related to pressure waves, was confirmed by Taylor et al (1978). Segmental 
and nonpropulsive, such waves were also found in non -IBS subjects. The 
abnormality persisted for upto 18 months even with symptomatic 
improvement, which occurred in 12 of 20 patients who were free of symptoms 
after one to three months treatment with bran or antispasmodic. 
(3) Increased activity in response to various stimulants (Whitehead et al 
1980) . 
Snape et aI (1978) showed increased slow wave activity in IBS patients only 
when stimulated by pentagastrin or cholecystokinin. There was no increase 
in basal contractions of the same frequency. 
(4) Delayed postprandial colonic motor response. 
The post prandial colonic spike and motor activity is delayed in IBS (Sullivan 
et al 1978). The effect is diminished by an anticholinergic agent (clidinium). 
Misiewicz et al (1966a) previously showed decreased postprandial activity 
upto 30 minutes after a meal. 
Small bowel motility. 
Small bowel transit time was variably reported as reduced or normal in IBS 
(Corbett et al 1981). Cann et aI (1983) reported that small bowel transit time 
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was reduced in diarrhoeic -IBS, but increased in constipated -IBS. There was 
no significant difference in gastric emptying. Of 34 patients who complained 
of pain during the meal transit, the pain was associated with arrival of the 
meal in the caecum in 74 per cent. Other symptoms often occurred 
simultaneously : nausea, abdominal distension, and urgency to defaecation. 
Early studies suggested reduced small bowel motor activity in IBS during 
pain, though there was no change when asleep or during normal activity 
(Horowitz and Farrar 1962). In the small bowel, during fasting, intermittent 
contractions interupt a relatively quiescent background with occasional 
migrating motor complexes (MMC). MMC travel distally from the proximal 
jejunum for a variable distance. Postprandially, irregular random contractions 
are the rule. There is great variation in the periodicity and duration of MMC 
in health (Kerlin and Phillips 1982) and in IBS (Kingham et al 1984). Kellow 
et al (1988) demonstrated changes in motor activity in the small bowel in 
continuous recordings of upto 29 hours duration. There was no difference 
between the IBS and control subjects in MMC speed or in distance 
propagated distally in the small bowel. In diarrhoeic -IBS subjects the MMC 
reached the ileum more often, and the interval between MMCs was shorter, 
than in constipated -IBS subjects. Prolonged propagated contractions were 
associated with pain in all 12 of the IBS subjects in whom they were 
recorded, and in three of six controls in whom it occurred. The pain was 
described as similar to their usual pain in the IBS sufferers. Non -propagating 
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contractions occupied more of the quiescent phase in IBS subjects, in whom 
maximum pressures were higher. These last two observations were not 
associated with the occurrence of pain. 
Kellow et al (1988) further suggest that stimuli may unmask dysmotility in IBS 
subjects. There was an increased small intestine motility response to several 
stimuli in IBS patients compared to controls. The changes precipitated by a 
fatty meal, infusion of cholecystokinin octapeptide, or ileal distension, were 
more notable in subjects with diarrhoeic IBS. 
Oesophageal motility. 
Smart and Atkinson (1987) showed abnormalities in oesophageal motility in 
IBS patients who did not have particularly prominent oesophageal symptoms. 
Lower oesophageal sphincter pressure was significantly reduced as in a 
previous study (Whorwell et al 1981) but there was no abnormality of 
oesophageal motility. Surprisingly 80 per cent of their 25 patients had 
evidence of inflammatory oesophageal disease but there was no correlation 
between severity of these changes, symptoms, and the degree of pH 
monitored gastrooesophageal reflux. In view of this suggestion of abnormal 
vagal function in IBS and the high prevalence of other putative autonomic 
dysfunctional conditions in the families of IBS patients (notably migraine), 
some authors have postulated an underlying generalised disturbance of 
autonomic function (Ester and Goultson 1973). 
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Illness Behaviour 
The nature of the potentially destabilising event. 
Changes in intestinal motility with stress. 
Stressful conditions, emotional and physical, seem to increase colonic 
pressure activity in IBS patients (Narducci et al 1985) and in healthy normal 
individuals (Almy et al 1949). Stress increased the proportion of 2 -4 cycle / 
min slow waves in IBS, while in normals the proportion was decreased 
despite the similarity in the resting state (Welgan et al 1985). Physical stress 
seemed to increase the gastrocolic response to a meal, though here 
emotional stress seemed to decrease the sigmoid colon pressure response. 
Narducci et al (1985) noted adaption to the stress, a repeated exposure 
evoking little increase in colonic motility in normal subjects. Surprisingly this 
adaptability was not examined in IBS subjects. Oral benzodiazepine seemed 
to ameliorate the effect of stress in IBS patients, although the potential 
influence of the adaptive response renders interpretation difficult. 
Acute emotional stress increases upper oesophageal tone. This manifests as 
globus hystericus - a well recognised phenomenon, though the mechanism 
is unestablished (Cook et al 1987a). Patients with nutcracker oesophagus or 
noncardiac chest pain have distal oesophageal contractions of greater 
amplitude than controls when exposed to psychological stress, though not 
under resting conditions (Richter et al 1986). Pain induced by cold immersion 
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of the hand slows liquid gastric emptying (Thompson et al 1986), while 
dichotamous listening stress appeared to have little effect (Cann et al 1983a). 
Roth et al (1953) could find no characteristic change in small intestinal motility 
during emotional stress within the context of a psychiatric interview. Nor were 
symptoms correlated with motility changes. Emotional stress (dichotamous 
listening) has been reported to reduce fasting MMCs (McRae et al 1982), and 
to reduce small bowel transit time. In IBS patients MMCs were reduced by 
stress, as they were in normal and in disease controls (Kumar and Wingate 
1985). Abnormal irregular contractions during stress seemed to coincide with 
symptoms in IBS patients. 
Involvement of non -gastrointestinal systems in functional disorders is well 
documented. Symptoms such as headache, insomnia, dyspareunia, and 
palpitations are frequently reported in IBS (Kirsner and Palmer 1958, Fielding 
1977, Whorwell et al 1986a). There is evidence to suggest that symptoms 
may result from disorders of smooth muscle in non -enteric structures 
(Whorwell et al 1986b). There is a much increased incidence of bladder 
dysfunction (in urodynamic studies) in IBS patients compared to controls. 
Detrusor instability is the most common disorder. It is not clear whether this 
has clinical significance, but the same group reported an increased incidence 
of urinary symptoms, notably frequency, urgency and nocturia in IBS 
subjects. (Whorwell 1986a). 
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The concept of the 'brain -gut' link has been suggested as a model for the 
disturbances which might provoke the IBS symptom complex : 
Disorder of smooth muscle or enteric nervous system is suggested by the 
evidence of altered myoelectric response to various stimuli, and altered 
smooth muscle function elsewhere. In this regard it is notable that although 
myoelectric response to cholecystokinin is exaggerated in IBS, no clear 
differences (qualitative or quantitative) in regulatory gut peptides have been 
demonstrated when comparing IBS subjects with normal controls (Besterman 
et al 1981). 
A central dysfunction is supported by the effects of psychological stress in 
IBS and by the importance of arousal in the abnormal motility and symptom 
profiles (Kellow and Phillips 1987). 
Overall no motility pattern specific to IBS sufferers has been established, 
either at rest or when patients are subject to various experimental stresses. 
There is no convincing evidence that a unique disturbance of gastrointestinal 
motility underlies the symptom complex in IBS. Such changes that are found 
do not readily explain nonenteric symptoms (Snape et al 1977, Taylor et al 






The nature of the potentially destabilising event. 
The influence of diet : fibre content. 
Although an increased incidence of IBS during wartime was reported in the 
English literature, Boas (1926), writing in the German literature, described 
how mucous colitis had become less common during the war. He suggested 
that this might be attributable to dietary changes, the wartime diet containing 
more residue and less meat. Dietary fibre is often recommended as treatment 
for IBS (Manning et al 1977) and is thought by some to be protective against 
development of the symptom complex (Mendeloff et al 1979). But the 
evidence in favour of this approach is not overwhelming. 
Fibre is a generic term describing several substances which have in common 
a propensity to increase stool weight and reduce gastrointestinal transit time 
(Kay 1982). This effect is achieved in one of two ways : 
(1) an increase in faecal water content. Cereal fibre is thought to act in 
this way, a property it owes to its structure rather than to its chemical 
composition (Robertson and Eastwood 1981). 
(2) an increase in the bacterial content of the stool, by which vegetable 





Were lack of dietary fibre, absolute or relative, a major factor in the 
maintenance of the IBS symptom complex, one would expect IBS patients to 
eat less dietary fibre than otherwise matched controls. This has not proven 
to be the case. Dietary histories suggest no consistent shortfall in dietary fibre 
intake in IBS patients compared to healthy controls (Hillman et al 1982, 
Fielding 1979). Likewise there is no difference in transit time or stool weight 
between IBS and controls (Goy et al 1976, Eastwood et al 1984, Hillman et 
al 1982). 
Such studies are confounded by the extreme variability of colonic function 
within the normal, healthy population (Wyman et al 1978, Drossman et al 
1982). Factors such as transit time, wet and dry faecal weight, faecal volume, 
and frequency of defaecation show enormous inter -individual variability and 
great intra- individual, day -to -day variability (Wyman et al 1978). This may 
reflect true variation in experience but might be a consequence of poor 
reproducibility of the method(s) of assessment (Eastwood and Kay 1979). A 
further confounding factor is the influence of psychological factors on stool 
characteristics ; personality profiles may predispose to low stool volume 
(Hillman et al 1982, Tucker et al 1981). 
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Illness Behaviour 
The nature of the potentially destabilising event. 
The influence of diet : food intolerance 
Dietary constituents have been implicated in the IBS symptom complex 
throughout the literature. In Chaudhary and Trueloves' (1962) seminal paper 
44 per cent of patients reported a connection between symptoms and some 
foodstuffs. In uncontrolled studies a gluten free diet improved symptoms 
(Pock -Steen 1973) though there is no evidence of coeliac disease in IBS 
patients. Nor is there evidence that lactase deficiency can account for 
symptoms in more than a very small minority of cases. Lactose intolerance 
is characterised by symptoms similar to those which occur in IBS. Intolerance 
does not effect all those who have lactase deficiency ; in part this is related 
to the dose dependant nature of the symptomatology. Lactase deficiency is 
relatively common and most studies suggest that it is not found more 
frequently in IBS patients than in the general population (Ferguson et al 1984, 
Pena and Truelove 1972). 
Alun Jones et al (1982) described how 14 of 21 patients with abdominal pain 
and diarrhoea felt that their symptoms improved with avoidance of certain 
specific foodstuffs. Six patients were subsequently challenged double -blind 
with their offending foodstuff and were able to identify 10 of the 12 challenge 
and control periods correctly. Rectal PGE2 was increased on the challenge 
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days and for upto 48 hours thereafter. The paper does not include details of 
the response in other than general terms, nor any indication of symptom 
duration. All patients certainly had diarrhoea. There was no psychological 
assessment. In another study, 36 of 49 patients with suspected food 
intolerance did not respond to a 'nonallergenic' diet. In eight patients a 
specific foodstuff was identified but in only two patients was the diagnosis 
sustained after blind challenge (Farah et al 1985). 
McKee et al (1987) studied a more diverse group of IBS patients. 40 patients 
showed little change in symptoms during an exlusion diet. 15 per cent 
responded symptomatically, though a further 12 per cent reported general 
improvement. The response rate was certainly best in those with 
predominantly diarrhoea. Exclusion diets are perhaps applicable in a minority 
of IBS patients in whom diarrhoea is the main complaint. Two hundred 
patients in whom other treatments had failed were treated with an exclusion 
diet (Nanda et al 1989). 48 per cent of the 189 who completed the three 
week period reported symptomatic improvement. 80 per cent of these 
responders were able to identify specific symptom -precipitating foodstuffs in 
a subsequent nonblind challenge. The absence of a placebo group, the short 
initial treatment period, and the non -blind nature of the rechallenge make firm 
conclusions difficult. No details are given of psychopathology, which one 
would expect in a proportion of such a large group said to have failed to 
respond to conventional therapy. 
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Bentley et al (1983) studied 27 patients with 'food allergy' and a mean 
symptom duration of five years. Seven patients reported no change in 
symptoms on an exclusion diet, or on subsequent food reintroduction ; four 
no consistent change ; and ten a consistent exacerbation by certain 
foodstuffs. In eight double -blind investigations, three diagnoses of food 
intolerance were substantiated. However in two cases there was already 
established milk intolerance, and all three cases were atopic by conventional 
criteria. 14 randomly selected patients were assessed by an independent 
psychiatrist using a standardised interview schedule. 12 had scores on the 
interview schedule indicative of psychiatric disorder ; in nine the diagnosis 
was neurotic depression. 
Pearson et al (1983) examined 23 patients who were attending an allergy 
clinic and who attributed symptoms to food allergy. The diagnosis was 
confirmed in four who each had typical atopic symptoms. In the remainder 
there was a high incidence of psychological disturbance, assessed by 
interview schedule. The most common diagnosis (10 patients) was of 
depression. Rix et al (1984) describe the psychiatric symptomatology in this 
group of patients and comment that prognosis seemed to be related to the 
strength of belief that food allergy was responsible, and that this might be 
critically influenced by the investigative process. 
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Fructose and sorbitol are natural constituents of many foods which seem to 
be malabsorbed in many normal subjects. The malabsorption can cause 
symptoms, particularly if the sugars are given together, which resemble the 
IBS symptom complex. In IBS patients the symptoms so produced seem 
more severe than in normal controls, though the prevalence of fructose 
malabsorption seems no greater in IBS patients (Rumessen and Gudmand- 
Hoyer 1988). 
Although alcohol has a laxative effect and is associated with dyspepsia 
(Langman et al 1982), there is little to suggest that alcohol abuse accounts 
for many cases diagnosed as IBS. However few studies have specifically 






The nature of the potentially destabilising event. 
Other possible influences 
Prolonged, probably post- infective, diarrhoea precedes the diagnosis of IBS 
in perhaps one quarter of sufferers (Chaudhary and Truelove 1962). It is not 
clear whether the diarrhoeic episode is simply the precipitant of medical 
attention seeking in previous non -reporters. 
It has recently been suggested on the basis of a preliminary study of four 
patients that a gonadotrophin -releasing hormone (GnRH) agonist might prove 
a useful treatment for IBS and provide insight into a possible neuroendocrine 
pathophysiology (Mathias et al 1989). 
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Illness Behaviour 
The psychological profile of the individual. 
Several of the earliest papers describing IBS refer to emotional factors such 
as anxiety, nervous tension, neuroses, and guilt (Bockus et al 1928, White 
1905, Allbutt 1884, Powell 1820). In their landmark paper Chaudhary and 
Truelove (1962) remarked that among the factors which appeared important 
in the genesis of IBS, psychological factors stood preeminent ; at least one 
such factor was present in 103 of the 130 patients. They also observed that 
almost all patients showed at least some measure of improvement, and that 
those patients in whom psychological factors were present fared worse, 
except where there was a major change for the better in their life situation, 
when the prognosis was much improved. 
Psychiatric illness. 
On the basis of a study of 14 patients Bouchier and Mason (1979) proposed 
a classification of IBS patients based on two distinct psychological profiles. 
In one class the gastrointestinal symptoms seemed a response to life 
changes or stress. In the other the symptoms were one manifestation of 
chronic psychological illness, predominantly depression. Hislop (1971) took 
this further, arguing that IBS is an affective disorder. He compared 67 
patients with 67 controls from a casualty department. 65 patients in the IBS 
group had evidence of depression or anxiety neurosis. 
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Gomez and Daily (1977) examined all patients presenting to a gastrointestinal 
clinic who were not accorded an organic diagnosis. On the basis of clinical 
judgement they suggested that all 96 such patients with 'functional disorder' 
were psychologically disturbed, though the nature of the disturbance was not 
always well defined. 32 per cent were depressed, 'chronic tension' was the 
diagnosis in 32 per cent, and hysterical states accounted for 18 per cent of 
the diagnoses. There was no control group. Yet most authors do not find 
evidence of psychiatric illness in all IBS sufferers. 
The use of more structured tools for psychiatric diagnosis and of a control 
group is no guarantee of greater validity of the conclusion. Liss et al (1973) 
and Young et al (1976) describe studies using a structured psychiatric 
interview from which diagnoses are derived using Feighners criteria (Feighner 
et al 1972). 72 per cent of 29 IBS patients (average age 44) had psychiatric 
illness, most frequently depression or hysteria, compared with 18 per cent of 
controls drawn from a medical clinic. However Feighners criteria give great 
diagnostic weight to physical symptoms, having been designed for use in the 
diagnosis of hysteria in young patients. The significance of such physical 
symptoms for psychiatric diagnosis may be much less in IBS patients. This 
difficulty is often encountered when using structured questionnaires for the 
diagnosis of depression, such is the weight given to physical symptoms in 
most such scales. 
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The Hospital Anxiety and Depression Scale attempts to address this difficulty, 
by diminishing the impact of somatic symptoms on the assessed probability 
of depression or anxiety state (Zigmond and Snaith 1983). However this may 
be to miss some of the point where the contention is that the the somatic 
manifestations are the only or predominant manifestations of psychological 
disturbance. 
Rose et al (1986) used the Depression Inventory (Beck et al 1961) to estimate 
the prevalence of depression in outpatients with functional abdominal pain. He 
reported that 68 per cent of those with IBS were depressed. But this was 
based on a threshold for diagnosis which was considerably lower than that 
usually used, and verified, with this questionnaire. This inventory also contains 
a high proportion of 'somatic' symptoms, as does the Hamilton Depression 
Rating Scale (HDRS), where 30 per cent of the score is so derived. Using the 
HDRS Kingham and Dawson (1985) considered 64 per cent of their 22 IBS 
patients to be depressed. But these patients clearly had severe, refractory 
symptoms ; indeed they had undergone a total of 38 operations for their 
abdominal symptoms. 
MacDonald and Bouchier (1980) studying consecutive referrals to a medical 
outpatient clinic, found psychiatric illness in 53 per cent patients where the 
diagnosis was of functional gastrointestinal disorder, and in 20 per cent in 
those with an organic gastrointestinal diagnosis. They used a standardised 




study of 79 patients with functional bowel disorder. The prevalence of 
psychiatric illness was 42 per cent in the IBS group compared with 18 per 
cent in a matched control group with chronic organic gastrointestinal disease, 
and eight per cent in a community control group. One study has shown 
conflicting results. Fava and Pavan (1976) reported a higher prevalence of 
psychiatric illness in the patients with an organic diagnosis. 
Of 31 patients described by Hill and Blendis (1967), in 19 the diagnosis was 
probably essential dyspepsia (there was no bowel disturbance) ; only six of 
his subjects would meet current IBS diagnostic criteria. He considered six 
patients to be depressed, five of whom responded well to antidepressants. 
In such series it is always difficult to establish which symptoms developed 
first. Liss et al (1973) considered that in 68 per cent of his patients 
psychological symptoms preceded somatic symptoms, whereas the reverse 
was true in only eight per cent. Young et al (1976) thought the relative figures 
were 55 per cent (psychological first) and 25 per cent (somatic first). 
Personality. 
Esler and Goulston (1973), using the Eysenck Personality Inventory (EPI) and 
the Institute for Personality and Ability Testing Anxiety -scale Questionnaire, 
found IBS patients (16, diarrhoeic type) obtained scores similar to patients 
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with chronic anxiety neuroses over a range of parameters. 
15 pain -predominant IBS patients were more introverted, but in other respects 
similar to the controls drawn from medical outpatients. A group of patients 
with ulcerative colitis were indistinguishable from the controls. The 
psychological profile of IBS patients is more disturbed than that of patients 
with similar reported symptoms, of similar duration, but who have an organic 
disorder (West 1970). 
IBS patients studied by Whitehead et al (1980) using the Hopkins Symptom 
Checklist (HSC) scored higher on all the global scales than the controls. The 
17 patients also had higher scores on five clinical subscales ; somatization of 
affect, interpersonal sensitivity, depression, anxiety, and hostility. There was 
no correlation with the severity of gastrointestinal symptoms. Palmer et al 
(1974), using EPI and Middlesex Hospital Questionnaire (MHQ) (Crown and 
Crisp 1966), suggested that IBS patients displayed a degree of neurotic 
personality structure. Their psychoneurotic- symptoms -score fell between that 
of the normal controls and that of the comparison group with established 
psychoneurotic disorder. 
Welch et al (1984) found IBS patients scored higher on MHQ scales for 
anxiety, phobic anxiety, and somatisation than normal controls. However the 
IBS patients were not different from a third group of patients with organic 
gastrointestinal disorders on these scales, nor on a Zung self- rating 
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depression scale. The numbers in the study are small, and the organic 
diagnoses include lymphoma, and colonic and gastric polyps (the group were 
drawn from patients awaiting endoscopy). Length of history is not stated. It 
is not clear whether the similarity reflects longstanding similarity in 
psychological profile or whether the profiles are converging as a 
consequence of short term, perhaps reversible, changes in one or both 
groups (one would not be surprised by increased psychological distress in 
such patients awaiting investigation). 
Bergeron and Monto (1985) found 70 per cent of IBS patients had 
psychopathology as assessed by the MMPI ; but half the patients were 
volunteers for a stress reduction programme. He considered that there were 
several patterns of psychological dysequilibria; 
1. inadequate dependency, characterised by a chronic pattern of 
depression. 
2. somatization: emotional problems tend to precipitate multiple physical 
complaints, often with denial, unrealistic optimism, and a resistance to 
psychological attribution. 
3. reactive depression characterised by excessive worry, anger, and 
denial. 
Whitehead et al (1988) found an increase in symptoms of psychologic 
distress on HSC in IBS patients compared to controls or non -reporters. A 
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similar pattern emerged comparing lactose malabsorbers seen in clinic with 
those seen in the community. It seems reasonable to conclude that IBS 
patients have greater evidence of psychopathology than normal healthy 
individuals and patients with similar gastrointestinal dysfunction but a specific 
organic diagnosis. 
There is a further possible confounding factor in the assessment of 
psychological parameters by questionnaire. Schema is a cognitive framework 
of beliefs, attitudes, and self perception which influences information 
processing and is stored in the memory. In major depression patients have 
a higher recall of 'depressed' words. Toner et al (1990) compared IBS 
patients with patients with major depressive illness. In the IBS subgroup 
meeting DSM criteria for a diagnosis of depression in the preceding year, 
there was recollection of a lower proportion of depressed words than in the 
depressed group. Thus IBS patient have less chance of seeing themselves 
as depressed. This accords with previous work (Latimer et al 1983) showing 
higher Lie test scores in IBS patients than in non -patient controls. Such 
higher scores can reflect ; 
1. deliberate faking of answers 
2. less candid self assessment 
3. less insightful assessment (though no less honest) 
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It is therefore evident that a substantial proportion of IBS patients meet 
diagnostic criteria for a variety of psychiatric diagnoses at the time the IBS 
diagnosis is made, and that on average they are more likely to have evidence 
of psychological distress or disturbance (even in the absence of a formal 
psychiatric diagnosis). In assessing the psychological status of IBS patients 
one must be aware that instruments designed to look for depression in 
putatively depressed subjects, or to seek psychopathology in normal 
populations, may be inadequate or misleading given the view(s) IBS patients 
may hold of their experiences. Despite the acknowledged limitations 
questionnaires do seem to offer an insight into possible psychopathology, 
provided they are interpreted with caution and circumspection. 
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Illness Behaviour 
The circumstances in which this interaction is occurring. 
The suggestion that stress was a significant factor in IBS appears early in the 
literature, with war the proposed 'stressor' (Da Costa 1871, Peters and 
Bargen, 1944). Chaudhary and Truelove (1962) recognised at least one 
psychosocial factor in 65 per cent of their 130 patients. Here the factors 
included difficulties with marital, family or business relationships. Marital 
difficulties were again emphasised by Hislop (1971) in his comparative study 
of 67 IBS patients and controls. Kirsner (1981) postulated that less dramatic 
events might also be important ; changing job, moving house, financial 
problems. 
Hislop (1971) further identified 'emotional distress in childhood' as being more 
common in IBS patients. Childhood deprivation was frequent in a second 
Hislop (1979) study though this was uncontrolled. Mendeloff et al (1970) 
found consistently higher scores of life stresses in IBS patients than in 
patients with ulcerative colitis or subjects from the general population. Death 
of a close relative was associated with IBS in a controlled study (Gomez and 
Dally 1977). Both IBS and ulcerative colitis were more frequently preceded by 
life events in the six months before the onset of symptoms than was 
appendicitis. Particular event classes were notable exits (death, separation) 
and undesirable social events (demotion, unemployment) (Fava and Pavan 
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76/77). Interestingly this group had previously shown no preponderance of life 
events coinciding with (or preceding) IBS, but the control group here was 
patients with ulcerative colitis. The importance of loss as a characteristic of life 
events has been stressed by several authors. 
The interaction between life events and symptoms, notably abdominal pain, 
is further shown in several studies examining the outcome of 'acute 
appendicitis'; comparing those patients in whom the appendix is histologically 
normal with those in whom there is histological inflammation. Harding (1962) 
first emphasised the importance of psychosocial factors in the former group, 
many of whom may well have IBS. Ingram and Evans (1965) found evidence 
of psychological disturbance in 83 per cent of women who had a normal 
appendix removed, but in less than 20 per cent in those with histological 
appendicitis. Of those with a normal appendix, at least 50 per cent were 
continuing to have pain one year later, as were 10 per cent of those with an 
inflamed appendix. The nature of the pain may give some clue as to the true 
diagnosis. Barraclough (1968) found that continuous pain was more common 
in those with noninflamed appendices and he confirmed that this group was 
more anxious. In a study of life events preceding appendicectomy both 
operation groups scored more highly for life events than a community control 
group (Creed 1981). But the pattern of events in those with noninflamed 
appendices more closely resembled that found in depressed patients than did 





feature in those with this 'depressive life event profile'. 
Craig and Brown (1984) analysed 'stressful life situations' in the year 
preceding onset of abdominal pain, and found differences between patients 
with a gastrointestinal clinic diagnosis of organic disease and those with a 
diagnosis of functional disorder. Again the striking characteristic of the events 
was that they carried a loss or 'goal frustrating' element and were 
comparable to those which often precede depression. Although stressful 
events of certain classes may be particularly powerful, it can be argued that 
in the development of a life events profile, less dramatic events may assume 
a powerful cumulative significance. 
Ford et al (1987) reported that there was a difference in experience between 
patients with functional and organic gastrointestinal disease. Anxiety - 
provoking life events were important only in those with psychiatric illness but 
31 per cent of those with a functional diagnosis had experienced psychiatric 
illness, and 35 per cent had experienced an anxiety provoking situation, prior 
to the onset of symptoms. He suggested that the interaction between the life 




Previous exposure to, and experience of, symptoms and illness behaviour 
A strong family history of abdominal complaints has been a recognised 
feature of IBS patients for several decades. Ryle (1928) described a familial 
tendency in childhood abdominal pain. The prevalence of current functional 
abdominal complaints was much greater in the families of IBS patients than 
in controls' families (Davidson and Wasserman 1966, Apley and Naish 1958). 
Children with chronic abdominal pain often have parents or siblings with 
similar complaints. But such children do not have parents who suffered from 
abdominal pain in childhood themselves (Christensen and Mortensen 1975). 
This suggests that imitative behaviour plays an important role, perhaps as 
important as any genetic component. Lowman et al (1987) found that IBS 
patients (and interestingly also non -patients) recalled more frequent childhood 
doctor visits, more numerous bowel complaints in childhood, and greater 
parental attention to illness, than did normal controls. Loss and separation 




Natural history of irritable bowel syndrome 
For many years IBS was regarded as a chronic relapsing condition ; patients 
were often perceived as chronic clinic attenders ; there was much therapeutic 
nihilism which persists in some clinicians today. However IBS patients are not 
a homogeneous group and the prognosis varies. There are some useful 
prognostic indicators. As long ago as the 1920s Dawson (1921) wrote that 
the prognosis was in his experience good if the associated constipation could 
be cured without resort to colonic irritants. After one to three years 30 per 
cent of Chaudhary's patients were symptom free (Chaudhary and Truelove 
1962). Determinants of symptom improvement included precipitation of the 
IBS by a dysenteric illness or a preceding major stressful life situation. In 
most studies length of history is not a useful guide to prognosis. Waller and 
Misiewicz (1969) commented that 'complaints continued much as before but 
patients felt so much better that symptoms faded into the background'. They 
considered that stress played an important part in 75 per cent of their 
patients, being the factor which most frequently changed experience into 
symptoms. One can understand the confusion surrounding prognosis in IBS 
when this paper is used in support of arguments that the prognosis is 'poor', 
quoting the low 'symptomatic response rate' of 12 per cent (Nanda et al 
1989) . 
40 per cent of patients were symptom free up to 20 years after presentation 
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with 'functional diarrhoea' (in half abdominal pain was also a feature). One 
fifth were still experiencing persistent symptoms. An alternative diagnosis had 
emerged in only three patients (Hawkins and Cockell 1971). Holmes and 
Salter (1982) found four alternative diagnoses in their 77 patients ; gastric 
ulcer, jejunal diverticulae, hyperthyroidism, and hypothyroidism. 44 per cent 
of the patients had persisting symptoms six years after initial diagnosis. 
Surprisingly Hastrup Svendsen et al (1985) found one case of pancreatic 
cancer and one of chronic pancreatitis in a 129 patient series. In a five year 
retrospective analysis 50 per cent of patients reported unchanged or worse 
symptoms independent of treatment. Abdominal surgery before diagnosis was 
an indicator of poor symptom control. In a five year prospective study Harvey 
et al (1987) found 68 per cent of patients became virtually symptom free. 
Good prognostic factors were male sex, predominant constipation, short 
history, and symptoms following a diarrhoeic episode. 
Misra et al (1989) studied the relapse rate in 28 patients who had previously 
improved on treatment with ispaghula husk and propantheline when such 
treatment ceased. They found symptomatic relapse rates of 82% and 46% in 
the placebo and continuing treatment groups respectively. All their patients 
had 'recovered completely' after four to six weeks treatment and the group 
is certainly not typical of IBS sufferers. No mention is made of initial fibre 
intake. 
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Treatment of irritable bowel syndrome 
The relapsing nature of IBS and the unknown pathophysiology render clinical 
treatment trials difficult. Outcome measures are difficult to define and have 
tended to rely on sequential symptom reporting or assessments of 'general 
wellbeing'. Generalisation from trials is often difficult because symptoms are 
not well defined and the psychological profile of the patients is often not 
considered. 
Antispasmodic agents 
Given the lack of a specific association between symptoms and motility and 
of a unique motility disturbance, it is not surprising that antispasmodic 
preparations have a limited efficacy in IBS. In the following discussion only 
trials with a placebo control arm are considered since without this 
interpretation is impossible. 
Phenytoin (Greenbaum et al 1973) is known to reduce smooth muscle 
contraction but in 12 patients treated for 20 weeks in a double blind 
crossover trial there was no advantage over placebo in improvement of IBS 
symptoms. 
Trimebutine was more efficacious than placebo in a double blind crossover 
study. However the treatment duration was only three days and the placebo 
55 
response rate was remarkably low at five per cent (Luttecke 1978). The 
advantage over placebo was not repeated in a second study from the same 
author (Luttecke 1980). Fielding (1981) demonstrated no advantage over 
placebo in 60 patients treated for six months. 
Mebeverine has been variably reported to be useful in IBS. Bertholet and 
Centonze (1981) in an 8 week study period claimed advantage over placebo, 
though the placebo response rate was 73 per cent, and his 69 patients were 
rather older than on most IBS series (mean age 57 years). Kruis et al (1986) 
could not demonstrate advantage over placebo in 70 patients treated for four 
months. 
Dicyclomine was claimed to affect a response in 94 per cent of 97 patients 
treated for two weeks (Page and Dirnberger 1981). 
Peppermint oil has been used in three trials of up to three weeks treatment 
duration. Two trials claimed benefit with response rates of 80 per cent (Dew 
et al 1984, Rees et al 1979). The third showed no advantage over placebo 
(Nash et al 1986). 
Loperamide is an opioid which increases small intestinal transit time and may 
decrease urgency or borborygmi. In 28 patients who had not responded to 
bran there was a favourable response to loperamide but this was also true 
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for placebo. Only diarrhoea and urgency showed a clinical and statistical 
response greater with loperamide (Cann et al 1984a). Hovdenack (1987) 
claimed a response rate of 100 per cent in 60 patients treated for three 
weeks. The patients are not well described and this result simply does not 
accord with general clinical experience. 
Domperidone, a prokinetic agent which reduces transit time, was 
disappointing in two studies of four and twelve weeks duration. (Cann et al 
1983a, Fielding 1982) A third study reported beneficial effect after four weeks, 
but here again the response rate is said to be 100 per cent (Milo 1980). 
Calcium antagonists may ameliorate exaggerated colonic motility response to 
food (Narducci at al 1985, Prior et al 1987) but this has not yet been 
reflected in clinical usefulness. Nifedipine gave disappointing results in 20 
patients treated for three weeks (Perez Mateo et al 1986). 
In 80 patients also given 30g fibre daily the response rate with Timolol over 
a six month follow up period did not differ from the placebo response rate. 
There was improvement in abdominal pain and doctors' general assessment 
in 65 per cent of both groups (Fielding 1981). 
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Dietary fibre supplements 
Many studies examining the effect of fibre supplements are flawed by poor 
quantification of baseline fibre intake, the lack of a control group, and 
insufficient characterisation of the dietary fibre supplement. Such trials are 
often short term. 
Prior and Whorwell (1987) describe 80 patients treated for 12 weeks with 
ispaghula. 82 per cent of the active and 53 per cent of the placebo group 
were globally improved but this seemed to reflect reduced constipation ; 
abdominal pain and bloating were not changed. Kumar et al (1987) showed 
that symptom score improved with daily supplementation of 10g, 20g, and 
30g of ispaghula husk in 14 male patients after 17 days. There was a 
significant increase in stool weight, most marked with 20g and 30g daily 
supplements. Whole gut transit time remained relatively constant. Fielding and 
Melvin (1979) described how an increase in dietary fibre intake caused 
improvement in symptoms. In this study those patients who did not improve 
were those whose fibre intake had not increased despite dietary advice. 
Manning et al (1977) studied 14 patients who received a daily supplement of 
20g cereal fibre for six weeks. The study was not blinded. Symptoms were 
improved and there was an associated change in colonic myoelectric activity. 
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However studies which have demonstrated little or no effect of fibre are in 
the majority and the concensus view is that while fibre supplement may 
reduce constipation it has little effect on the other complaints which comprise 
the IBS symptom complex. 
Hillman et al (1984) followed 30 IBS patients for up to three years. Initial fibre 
intake correlated poorly with symptoms and bowel habit. Half the patients 
were improved by a mean increase in daily fibre intake of 6.7 g /day. There 
was no difference between this and the placebo group. No clinical score 
predicted individual course. Soltoft et al (1976) described a placebo controlled 
double -blind trial of 59 patients. The active group received 30g bran daily 
without significant symptomatic response after six weeks. Baseline fibre intake 
was not given. In a double blind trial involving 77 patients there was no 
difference in response between the placebo group and that taking a 
vegetable fibre supplement over 12 weeks (Longstreth et al 1981). 
Arthurs and Fielding (1983) found no difference from placebo in 80 patients 
after four weeks using ispaghula ; active and placebo response rates were 
both of the order of 70 per cent. Cann et al (1984b) studied 38 patients in a 
non -blind, controlled study over four weeks. 47 per cent of active treatment 
subjects considered themselves improved on 10 -30g wheat bran supplement 
daily ; not significantly different from the placebo subjects. Bran did reduce 
constipation. Lucey et al (1987) achieved response rates of approximately 75 
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per cent in treatment and control groups with wheat bran supplements for 12 
weeks. 
Arffmann et al (1986) showed increased stool weight but no effect on 
symptoms compared to placebo in 20 patients taking a 30g supplement of 
wheat bran for six weeks. There is insufficient detail in the paper to allow 
assessment of the placebo response. 
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Antidepressants 
From the prevalence of depressive symptoms and possible depressive illness 
in IBS patients, one would anticipate that antidepressants would be 
efficacious in a substantial proportion of such patients. However the use of 
antidepressants in IBS remains contentious. Where a diagnosis of depression 
is made there is a clear place for consideration of antidepressant therapy. But 
in those patients not thought to be suffering form a depressive illness 
antidepressants may still be advocated. Of course tricyclic antidepressants 
have anticholinergic effects but peripheral anticholinergics have yielded 
disapppointing results in IBS. Those patients who do respond may have an 
unrecognised depression. 
Further difficulties are raised by the time course of the improvement in those 
studies where there is benefit ; symptomatic response occurs long before a 
mood lifting effect would be expected, often within the first ten days of 
treatment (Hislop 1971, Heefner et al 1978, Myren et al 1982, Steinhart et al 
1981). It is interesting to note the similarity here with emotionalism after brain 
injury, notably after acute stroke which likewise responds variably to 
antidepressant medication and often within 72 hours. There are no double - 
blind controlled trials of longer than eight weeks of antidepressants in IBS 
and in the shorter trials the outcome measures, and the duration and 
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characterisation of symptoms, is poorly defined. It is not possible to make a 
firm judgement on the efficacy of antidepressant treatment in IBS. 
Combination treatments also have advocates. Ritchie and Truelove (1979) 
used varying combinations of hyoscine (an anticholinergic antispasmodic), 
lorazepam (a benzodiazepine), and fybogel. 38 per cent of 98 patients 
improved over three months. None of their placebo patients improved and 
they concluded that there was little benefit from placebo in IBS. In a 
subsequent non -placebo trial similar improvements were shown with 
mebeverine, fluphenazine and nortryptiline, and bran (approx 20g daily). The 
combination of all three was most powerful. Although the authors comment 
that lorazepam was not more efficacious in those with high anxiety scores, 
nor fluphenazine and nortriptyline in those with high depression scores, the 
figures on which these interpretations are made are not given (Ritchie and 
Truelove 1980). Lancaster -Smith (1982) claimed benefit from a fluphenazine 
and nortriptyline combination, although only one of eight examined 
parameters was improved. 
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Psychotherapeutic approaches 
Upto 10 one hour sessions of individual psychotherapy caused reductions in 
symptoms at three and twelve months in a contained trial of 101 outpatients 
(Svedlund 1983). Schonecke and Schuffel (1975) had previously shown no 
such improvement in a shorter term study. Hislop (1980) found 
psychotherapy of benefit in 60 patients followed up for two years. Whorwell 
et al (1984) found hypnotherapy highly effective in 30 patients with severe 
refractory IBS (mean of six previous treatments) after seven half -hour sessions 
over three months. There was no deterioration after 18 months. The placebo 
group, who received supportive psychotherapy, also improved, but to a 
significantly lesser degree. The support comprised explanation and discussion 
of symptoms and of emotional problems. 
Disturbing thoughts are common in normal people and often relate to health 
worries. Such thoughts and their interaction with experiences may prompt the 
sufferer to seek 'reassurance'. Although the reassurance may reduce short 
term anxiety, the nature of the process of reassurance may serve to increase 
the perceived validity of the distress and thereby increase longer term 
disturbance. This may provoke further reassurance seeking and a vicious 
cycle is established (Warwick and Salkovskis 1985). Systematic prevention of 
this reassurance -seeking behaviour has been developed in the management 
of obsessional states and perhaps the technique is applicable in IBS. 
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Certainly repeated investigations often serve simply to confirm the IBS patient 
in the view that 'there must be something wrong' (Kreitman et al 1965). 
Reassurance must be appropriate and directed, and the reassurer should be 
as aware of the emotional concerns of the patient as of their physical 
symptoms. 
Cohen and Reed (1968) described how 'nervous diarrhoea' was improved by 
a desensitisation programme. This experience is of limited relevance since the 
'nervous diarhoea' discussed occurred in only two of the six described cases, 
and was characterised by frequency of defaecation precipitated by travelling. 
The subjects would not fulfill most criteria for a diagnosis of IBS. 
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Behavioural model 
Illness behaviour theory does seem to be a valid framework within which to 
construct a model of IBS. Pilowsky first described the concept of abnormal 
illness behaviour and has subsequently described the necessary 
characteristics ; 
'the persistence of an inappropriate or maladaptive mode of 
perceiving, evaluating, and acting in relation to ones own state 
of health, this despite being offered (by the doctor) an accurate, 
reasonable, and lucid explanation of the illness, its nature and 
its treatment, with opportunities for discussion, clarification, and 
negotiation based on an adequate assessment of all biological, 
psychological, and social factors.' 
( Pilowsky 1969) 
Behaviour theory suggests that rewarded behavioural patterns will be 
repeated or copied. It is known that learning can influence gastrointestinal 
functions such as gastric acid secretion or colonic motility, particularly if 
feedback loops are employed (Miller 1977). The development of a chronic 
illness behaviour profile is facilitated by rewarding illness behaviour. This 
facilitation may be particularly important in childhood. 
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Based on insights such as these and on the features of IBS, Latimer (1981) 
has proposed a behavioural model for IBS. This model rests on three major 
propositions ; 
1. That events, symptoms, and behaviours are independant 
variables. The same physical stimuli can produce different 
behavioural responses, motor and emotional, in the same 
individual as well as in diverse individuals (Schachter and Singer 
1962). It is counterproductive to attempt to place the event, any 
subsequent reported symptoms, and any consequent behaviour 
on a single linear axis since the confounding inputs from factors 
other than the initiating 'event' play such a powerful role in 
shaping the overall response. 
2. IBS is a a continuous disorder with no clear demarcation from 
normal experience. There is no single characteristic which sets 
the IBS patient apart. 
3. There is a familial predisposition to certain kinds of behavioural 
response. These patterns may be regarded as unlearned and 
unadaptive. The behaviour patterns observed in IBS may 
originate in such unlearned response patterns. 
This behavioural model can be usefully refined by integrating aspects of the 
phenomena of somatisation and amplification. 
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Amplification is described as the consequence of a heightened attention focus 
on bodily sensations, and / or a tendency to select out and concentrate on 
certain relatively weak and infrequent sensations (Barsky et al 1988). It may 
be accompanied by a disposition to react to such sensations with an affect 
and cognitive process which intensifies them and makes them alarming, 
ominous, and disturbing (Barsky 1979). A disposition to respond in a certain 
way is a personality trait, a persisting characteristic. The trait termed 
neuroticism is particularly noteworthy in his discussion. The tendency to 
report and experience a wide range of negative emotions, neuroticism is a 
reliable, valid and stable construct with associations with introspection and a 
tendency to depressive symptomatology (Watson and Clark 1984). It can be 
argued that the degree to which traits are expressed at a given time is 
influenced by emotional state. 
These concepts have much in common with those used to describe 
somatisation. This has been defined as ; 
'an idiom of distress in which patients with psychosocial and 
emotional problems articulate their distress primarily through 
physical symptomatology' 
(Katon et al 1984). 
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The behavioural aspects were subsequently emphasised ; 
'the expression of personal and social distress in an idiom of 
bodily complaints with medical helpseeking' 
(Kleinman and Kleinman 1985). 
Somatoform disorders have been divided into four classes; 
1. In conversion states the major dysfunction is in behaviour. Ideation and 
communication may be unaffected. 
2. In hypochondriasis, behaviour is often least affected, the disruption 
being principally one of ideation and communication. 
3. Somatiform pain is also characterised by abnormal ideation and 
communication with relatively little behavioural disturbance. 
4. Somatisation is distinguished by elements of dysfunction in all three 
domains; ideation, communication and behaviour. 
Somatoform disorder need not be diagnostic category and Goldberg has 
emphasised that somatisation does not imply psychiatric illness (Goldberg 
1979). However somatic presentation is extremely common in depressive 
illness ; the majority of patients with psychiatric illness do not present with 
psychological compliants, but with physical symptoms alone (Goldberg 1979, 
Bridges and Goldberg 1985). The consulting behaviour of such patients is 
determined by their attribution of the symptoms to a physical disorder and 
they seek help for the somatic manifestations only. 
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Using these insights IBS symptom presentation may be conceptualised as 
originating in an unlearned, maladaptive response which may be consolidated 
into personality structure. This response will be manifest in behaviour only 
when external or internal events are perceived as sufficiently threatening to 
evoke the response. The threshold for this response may vary according to 
the emotional state and mood of the individual and the response itself may 
be influenced by adaptive learning, by which the response is altered to better 
effect amelioration of the disruption caused by the events. 
Elements of the maladaptive response may persist because of advantages 
they confer. 
1. The help- seeking behaviour may increase social interaction which may 
of itself be sufficient reinforcement. These motives are of course 
dominant themes in Balint's theories (Balint 1957). 
2. Somewhat paradoxically the mood disorder, particularly depression, 
may be reduced by somatisation. The maladaptive response may 
permit avoidance of responsibility or blame (Goldberg and Bridges 
1988) . 
3. This may be the only method of distress -communication available to 
the individual, or may be the only language of such distress - 
communication which is socially accepted. This sociocultural influence 
may be particularly important ; somatisation is the norm in most of the 
worlds' cultures. 
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Several important differences have indeed been noted between somatisers 
and non -somatisers in studies of depressive illness. The psychiatric disorder 
tends to be more longstanding in somatisers, and marraige relationships tend 
to be poorer. Interestingly, however, there tends to be less disruption of 
social, family, and occupational networks, and less anxiety, in those patients 
who somatise their distress (Goldberg and Bridges 1988). 
But somatisation has disadvantages too, though they may not be perceived, 
or indeed perceivable, from the patients perspective. Psychiatric disorder may 
not be recognised, diagnosed and treated. Inappropriate investigations may 
be ordered, and iatrogenic disease needlessly precipitated. Abnormal illness 
behaviour patterns may become established. Kirsner (1981) proposes that 
IBS can be regarded as a negative interaction with medical systems. 
These observations may have implications for the management of IBS. 
Abolishing symptoms may not be an appropriate objective where they arise 
as an unlearned coping response. Rather it may be more rational and fruitful 
to seek to influence the mechanisms by which the response is refined and 
the behaviour determined, accepting that at times the response (the symptom 
complex) is likely to recurr. 
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Goldberg describes four stages in this process of reattribution ; 
1. assessment. 
2. changing the agenda, focussing away from the somatic complaints. 
3. encouraging recognition of the link between the somatic symptoms and 
the psychic distress. 
4. development of a coping strategy for recurrence of the response. 
This does not necessarily require patient insight into the pathogenesis of the 
maladaptive response, but it does require that the consulted physician be 
alert to the possible psychological determinants of somatic presentations. 
Some general practitioners seem to produce more somatisation than others, 
though this may reflect prior selection of patients with the propensity to so 
react, rather than the general practitioner influencing the reaction per se. The 
behaviour and future response of the IBS patient will be forged in the 
conduct of the doctor -patient relationship. 
However the conceptual framework of somatisation tends to perpetuate the 
duality of emotional and physical disorders. A more useful approach may be 
to consider emotional and motor responses as part of the totality of 
behaviour (Weiner 1989). All behavioural acts (emotional and motor) can be 
seen as neurally mediated responses which occur in relation to the conditions 
under which they occur (ie behaviour, voluntary and reflex, is intrinsically 
conditional). 
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It follows that adaptability (and maladaption) is likewise conditional. It is, after 
all, accepted that associative conditioning can influence behaviour (ie stimuli 
can be recognised), and that operant conditioning can reproduce the reflex 
behaviour under different conditions. 
From the illness behaviour model and the observations regarding IBS which 
I have considered, there developed a model of IBS based on the proposition 
that the symptom complex and medical -help- seeking behaviour were the 
product of an interaction between three influencial domains ; soma, psyche, 
and circumstance. These could be represented as apices of a triangle (Ford 
et al 1982). The studies described here examine elements of this model and 
the thesis suggests refinements of this behavioural approach which may allow 
greater insight into the development, natural history, and treatment of IBS. 
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To assess the correlation between gastrointestinal symptoms and general 
well -being in IBS. 
To investigate whether a fibre supplement given as tablets will influence 
gastrointestinal symptoms or general well -being in patients with IBS. 
To assess the placebo response in patients with IBS. 
To register psychopathological variables in order to investigate possible 
correlation between psychopathology, irritable bowel syndrome, and the 
putative therapeutic effect of dietary fibre. 
To investigate the correlation between questionnaire and visual analogue 
scale assessments of anxiety and depression in patients with irritable bowel 
syndrome. 
To measure salivary IgA concentration in IBS patients and investigate any 
correlation between this and psychopathology or treatment response. 
To consider whether alcohol plays a part in the aetiology of the IBS symptom 
complex. 
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To assess the possible usefulness of platelet serotonin and urinary 
metanephrine as biochemical indicators of psychopathological variables in 
IBS. 
To examine the 5 year prognosis of IBS and consider psychopathological 
influences on the 5 year outcome. 
To consider the impact of attendance at a specialist GI clinic on the GP 




Statistical advice was obtained from the Department of Medical Statistics of 
The University of Edinburgh. As a result of this advice Student's t -Test was 
used to compare mean levels between groups of patients, because of its 
robustness to departures from normality of distribution with reasonable 
sample sizes. In the tabulated results mean values and standard deviations 
(SD) are accompanied by the range. Where the distributional assumption is 
threatened and variances do not permit the use of parametric tests, 
appropriate nonparametric Mann Whitney U test is used to compare groups. 
Analysis of association between pairs of variables was by Spearman 
coefficient of rank correlation (R) to avoid distributional assumptions. The 
product- moment correlation coefficient (r) is also given where appropriate in 
recognition of its greater sensitivity and reliability. 
Analysis of the treatment trial was on an 'intention to treat' basis, using the 







Subjects were recruited from the outpatient clinic of a specialist 
Gastrointestinal Unit. All had been referred by their general practitioner. The 
patients were asked to consider participating in the therapeutic trial after the 
diagnosis of IBS had been established in the outpatient clinic. This would 
usually take one or, less frequently, two visits. No medications were given or 
dietary advice offered at this stage. Patients were recruited predominantly 
from the clinic of one consultant gastroenterologist, though the units' other 
two gastroenterology consultants referred some patients. 49 suitable patients 
were identified and recruited over a 9 month period. Patients were all 
approached by the investigator in the clinic and gave informed consent in 





The diagnosis of irritable bowel syndrome was made on the basis of the 
following features : 
1. an altered bowel habit of at least 6 months duration unaccompanied 
by rectal bleeding 
2. the presence most days of abdominal pain 
3. relief of pain with defaecation 
4. abdominal distension. 
Only those in whom the altered bowel habit was constipation (straining to 
pass hard stool less than 3 times a week) or alternating frequent defaecation 
and constipation (as defined above) were included. The diagnosis was not 
sustainable in the presence of features of systemic disorder particularly weight 
loss, sweats, or eye or joint symptoms. 
All subjects had normal general, abdominal and sigmoidoscopic examinations. 
Rectal biopsies were taken in 42 cases; all were normal. In all subjects full 
blood count, erythrocyte sedimentation rate (ESR), urea and electrolytes, and 
thyroid function tests were within the laboratory's normal reference range. 





All subjects were outpatients with a diagnosis of IBS as defined above, aged 
between 18 and 80 years. The following were grounds for exclusion : 
Irritable bowel syndrome with diarrhoea as the predominant bowel habit 
without periods of constipation. 
Patients currently using fibre supplements, or in whom such supplementation 
had previously been used as a sustained treatment for their symptoms. 
Use of the following medications ; laxatives, anticholinergic agents, drugs 
with anticholinergic activity, opioids with constipating effect, H2 blockers, 
ganglionic blocking drugs. 
Patients with a concomitant or previous diagnosis of anxiety neurosis or 
depression were excluded, as were those in whom specific psychotropic 




The presence of other diseases of the gastrointestinal tract or of colonic 
diverticula on barium enema. 
Significant indigestion. 




Trial Design : a double -blind, placebo -controlled, randomized trial. 
Subjects were randomised to receive either concentrated fibre or placebo 
tablets. Randomisation was by the supplier of the tablets, based on random 
number tables which designated the trial number active or placebo. The 
binary code was not revealed to the investigator until after the clinical trial 
was finished, and the identity of active and placebo groups was revealed only 
after statistical analysis was complete. The fibre tablet contained a mixture of 
cereal and fruit fibre; 44% of its 624 mg was analysed and measured as 
dietary fibre. The placebo, a mixture of starch, calcium phosphate, and 
lactose had a dietary fibre content of 29 mg and looked identical to the active 
tablet. All subjects were instructed to take 5 tablets 3 times daily, at 
mealtimes, accompanied by a large glass of water. Subjects in the 
concentrated fibre tablet group received a daily supplement of 4.1 g dietary 
fibre, those in the placebo tablet group 0.4 g. 
A one -week run -in period (week 0) was followed immediately by a 12 week 
test treatment period. Symptom assessments were performed at the start of 
weeks 0 and 1, and at the end of weeks 4 and 12. The daily dose of test 
tablets was estimated by the patient ; this assessment of compliance was 
coupled with a request to return any unused tablets. 
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Possible side -effects and concomitant medication were also recorded. At the 




Symptom assessment : gastrointestinal symptoms 
At the recruitment visit subjects were asked about specific gastrointestinal 
symptoms. In the week before treatment was started (week 0), the subjects 
completed a seven day diary of daily bowel movements, type of stool and the 
occurrence of abdominal pain. [Appendix 1] The week -long diaries were 
completed again during weeks 4 and 12. From the diary three scores were 
calculated : 
1. pain score 
The sum of each daily recording 0 (absent), 1 (slight), 2 (moderate), 
3 (severe). Where more than one entry was made in a single day the 
highest was used for that day in the summation. 
2. frequency score 
The number of stools in the week. 
3. constipation score 
The consistency of each stool was recorded as follows ; 
hard or broken (1), pellety (2), normal (3), soft (4), watery (5). 
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The constipation score was calculated as the sum of the daily 
(number of stools x consistency). The lower this score, 
the less frequent and harder the stool. 
A single investigator interviewed all subjects at recruitment and at the end of 
weeks 0, 4 and 12, recording the parameters shown below. 
Symptom Score 
urgency to defaecation yes (1) / no (0) 
constipation 0 -3 
abdominal pain 0 -3 
relief of pain at defaecation yes (1) / no (0) 
mucous in stool yes (1) / no (0) 
abdominal distension or bloating 0 -3 
flatulence or borborygmi 0 -3 
sensation of incomplete evacuation yes (1) / no (0) 
The total score (maximum 16) was taken to represent the global symptom 
score. 
86 
Symptom assessment : general evaluation of well- being. 
Each subject was asked at the end of the study if they felt 'generally better', 
'unchanged', or 'worse' for having taken the tablets. 
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Methodology 
Assessment of fibre intake 
Between recruitment and the start of week 0 each patient was interviewed 
by a single dietician. A 24 hour recall evaluation of carbohydrate, fat, protein, 
alcohol and dietary fibre intake was obtained. The dietician was unaware of 
symptom severity or character, and offered no dietary or other treatment 
advice. Daily dietary fibre intake was calculated using data from McCance and 
Widdowson's the composition of foods (Paul and Southgate 1978). 
There are several approaches to the assessment of dietary intake. I was 
particularly interested in dietary fibre intake and in comparing groups of 
subjects. The 24 hour recall method was chosen because of its ease of 
administration and validity in group comparisons. The subject is asked to 
recall their exact intake for the preceding 24 hours. Recent memory may be 
more accurate, particularly for quantity, than a general diet history approach. 
Although there is significant under -reporting of intake by this method, analysis 
of variance demonstrates good correlation between actual and recalled values 
(Madden et al 1976). 
But individuals diets' vary from day to day. Comparing a single 24 hour recall 
assessment with the daily average from a seven day diary, Young et al (1952) 
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found very close correlation for nutrient divisions; indeed the group means 
were 'interchangeable'. 
However, self- recording may influence such results and most studies show 
significant day to day variations in the 24 hour recall profile of individuals 
(Balogh et al 1971, Heady 1961). However these disadvantages need not 
invalidate 24 hour recall as a method for assessing and comparing the 
dietary profiles of groups of subjects. There is considerably less day to day 
variation in the mean intake of groups of subjects. Heady (1961) and Hankin 
et al (1967), in groups of 116 and 93 subjects, confirmed large day to day 
individual variation, but demonstrated stability of the group mean. Thus, 
although 24 hour recall is not a valid tool for assessing individual intake, it 




Assessment of anxiety and depression 
1. The Delusions- Symptoms- States Inventory (DSSI) 
At the recruitment visit subjects were asked to complete a single -page, 14 
item questionnaire examining anxiety and depression based on the Delusions - 
Symptoms- States Inventory (DSSI) of Foulds and Bedford. [Appendix 2] The 
DSSI was developed as a self report measure which would facilitate 
classification of psychiatric illness (Foulds and Bedford 1975). The inventory 
includes assessments of 'states of emotional disturbance', which comprise the 
first and lowest class (Class 1) in the four class hierarchical model. 
Depression and anxiety are two of the three dysthymic states in Class 1. The 
states are more descriptive than diagnostic - an individual falling into one of 
these states might be said to be 'emotionally stirred up'. It might be said 
that most individuals experience these states at some time. It is perhaps 
easier to see an association between circumstances and these states, than 
between events and the factors which make up the higher classes. 
Each class in the hierarchical model (Class 2 [symptoms], Class 3 
[delusions], and Class 4 [disintegration]) comprises several sets examining 
a range of emotional phenomena and psychiatric symptomatology. Each set 
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has seven items, for each of which the response scores 0 - 3. The maximum 
response is therefore 21 for each of depression and anxiety. It was decided 
arbitrarily during formulation of the inventory that a score of 4 or more should 
indicate true states /symptoms within the sets. The DSSI has been validated 
in psychiatric patients and in normal UK subjects (Foulds and Bedford 1975). 
2. Visual analogue scales 
A line rating visual analogue scale (VAS) was explained and an example 
illustrated and completed. [Appendix 3] The VAS is expressed in mm, 
measured from the zero point which represents the minimum available 
expression of anxiety or depression. 100mm is the maximum score. 
Measurement of the VAS score was blind to all other assessments of 
symptoms. Visual analogue scales have been validated as an instrument for 
assessing aspects of mental state, particularly anxiety or depression (Ingham 
1965, Ingham and Miller 1976). 
The subjects completed the VAS line rating and questionnaire exercises in 
private although the same investigator throughout asked about any difficulties 
before the record was collected. 
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3. Critique 
Personality attributes and emotions, such as depression and anxiety, are 
difficult to define, to differentiate, and to quantify. Clinical impression is not a 
satisfactory basis for their study. A reproducible, valid system of assessment 
is required. To this end many questionnaires have been devised. A frequent 
drawback of these instruments for examining psychological variables is that 
they fail to differentiate between personality traits and symptoms (Foulds 
1965). If the purpose is to examine severity of an illness or to gain 
diagnostically significant information, symptoms and signs of illness should be 
sought in the questionnaire. However if one is seeking to explore relatively 
enduring personality attributes, the questionnaire must seek to reveal 
personality traits. 
One has to recognise the limitations inherent in the use of questionnaires. 
(1) The reliability of the informant (usually the patient) may vary, and 
their assessment or account may not equate with that of an 
observer. This is perhaps best demonstrated by obsessional 
traits which the patient may not recognise (or report) as extreme 
behaviour or emotion, but which most observers would regard 
as extreme. 
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(2) The subject may be reluctant to reveal personal feelings; 
'defensiveness'. This may be accompanied by a pattern of response 
characterised by a greater willingness to acknowledge physical or 
somatic symptoms than 'psychological' complaints. (Walton and Mather 
1962) . 
(3) Spurious agreement is a confounding overeagerness to admit 
symptoms - the opposite of 'defensiveness'. 
(4) Answers may be influenced by the social desirability of the 
response (Edwards 1953). 
(5) Subjects may, in general, acknowledge extremes of behaviour or 
emotion (end- users), or may tend to seek to place their experience in 
the middle ground (middle- users). 
(6) Positional bias in responses can arise from the spatial 
arrangement of the questions and possible responses. 
(7) Scoring on multiple response questions gives rise to further 
unique difficulties as a consequence of 'conceptual distance' 
(Goldberg 1972). For the respondent the difference between, for 
example, never and very infrequently may be much greater than 
that between very infrequently and frequently. But they are 
presented as though the distance was the same. Goldberg calls 
this a 'between column problem'. We further assume that the 
distance between given 'points' on one question is of equal 
significance to the distance between 'points' on another ; a 
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'between row problem'. 
(8) Linear (graphic) rating scales (Guildford 1954) allow greater 
freedom of response but the above limitations still apply. One 
partial solution is to use a 'thermometer scale', defining only the 
two extremes (for example - never & constantly). 
Meites et al (1980) highlight the difficulties in defining and measuring 
emotions, particularly depression and anxiety. There was considerable overlap 
between depression and anxiety in a comparison of the Beck Depression 
Inventory, the Zung Self Rating Depression Scale (ZSDS), the Taylor Manifest 
Anxiety Scale, and the Neuroticism component of the Eysenk Personality 
Inventory. 
There are difficulties too in differentiating the intensity, frequency, and duration 
of emotions. This is particularly important when attempting to delineate the 
relationship between somatic complaints and such psychological variables. 
ZSDS identified 30% of depressed patients in medical outpatients but missed 
those patients whose depression presented as a somatic illness. Such scales 
clearly measure a degree of 'emotionality' but they may not detect a specific 
state. While this limits the use of such scales in a diagnostic role, it may not 
be a critical disadvantage in therapeutic terms since the 'emotionality' may 
respond to treatment, whatever its basis. Nor need it be a critical hindrance 
in the exploration of a possible aetiological role for emotional factors in 
conditions which present with predominantly physical symptoms. 
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However these limitations do have important implications for research, not 
least in rendering all but impossible the comparison of groups assessed 
using different methods. Moreover the relationship between somatic 
symptoms and emotion is not static. The temporal relationship between the 
onset and severity of the symptoms and emotions may be crucial, but this 
interrelationship is often difficult to disentangle, particularly in retrospective 
studies. 
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Results and Analysis 
Subject characteristics 
The age range and sex ratio are similar to most series of irritable bowel 
patients in the literature [Table 1]. The daily dietary fibre intake is likewise 
similar to that in the population from which the patients are drawn (Eastwood 
et al 1984). These patients are certainly not notable for a diet particularly 
lacking in dietary fibre. Pretreatment dietary fibre intake correlated with 
reduced constipation [Table 3]. 
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Results and Analysis 
Table 1. Subjects : Initial characteristics 
age (years) 
sex ratio (male:female) 
daily fibre intake (g) 




global symptom score 
mean SD range median 
39 13 18 - 76 39 
17 : 32 
20.2 6.1 7 - 31 20 
45.8 44.8 3 - 240 12 
6.1 5.1 0 - 17 6 
10.7 7.3 2 - 30 8 
33.8 30.2 3 - 141 25 
7.3 2.4 2 - 12 8 
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Results and Analysis 























* p < 0.05 
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Results and Analysis 
Psychometric assessment 
The patients found little difficulty in completing the visual analogue 
assessments of depression and anxiety. They seemed a little more defensive 
about the questionnaire and this certainly took considerably longer for most 
patients to complete. Despite this the psychometric tests took less than 10 
minutes to administer in the vast majority of patients, none of whom were 
unwilling to complete the assessment. There was a correlation between the 
questionnaire and visual analogue scales (VAS) measures for both anxiety 
and depression [Table 4]. 
There was no significant correlation between the levels of anxiety or 
depression and the duration of symptoms [Tables 5,6]. 
The only significant correlation between symptom severity and the 
psychological tests was between initial pain score and depression line rating 
score, a further illustration of the relationship between perception and 
reporting of pain, and psychological parameters [Table 6]. 
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Results and Analysis 
Table 4. Assessments of anxiety and depression. (n = 49) 
Anxiety Depression 
Questionnaire (positive responses) 
mean 1.8 1.1 
SD 1.7 1.1 
range 0 -7 0 -5 
Visual Analogue Scale (mm from zero end) 
mean 39 30 
SD 16 14 
range 11 - 89 4 -70 
Correlation 
r (product- moment coefficient) 0.64 0.73-* 
R (Spearman rank coefficient) 0.52 " 0.51 
*** p < 0.001 
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Results and Analysis 
Table 5. Association between anxiety and initial symptom 




global symptom score 






0.17 0.10 0.20 0.15 
-0.04 -0.07 -0.21 -0.27 
0.01 0.04 0.20 -0.19 
-0.02 -0.11 0.09 -0.10 
0.09 0.13 0.03 -0.01 
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not significant 
Results and Analysis 
Table 6. Association between depression and initial 




global symptom score 






0.30 ' 0.24 0.34 ' 0.32 ' 
-0.03 -0.06 -0.05 -0.09 
0.01 -0.10 -0.01 -0.08 
0.06 0.10 0.05 0.05 
0.11 0.16 0.05 -0.03 
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* p < 0.05 
Results and Analysis 
The changes in objective symptom scores are (in general) greatest in those 
patients with the highest initial scores [Tables 7 - 10]. This may again be a 
return to the mean phenomenon, although less fastidious recording of bowel 
habit or altered perception of stool consistency might also have contributed. 
The change might also reflect an association between perceived symptom 
severity and propensity to respond to 'treatment'. In this regard it is notable 
that the global score does not follow this trend. Perhaps this more 
complicated assessment is less directly susceptible to the interaction between 
symptom (experience) perception and response to consultation. 
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Results and Analysis 
Table 7. Association between the change in pain score and 
initial parameters. (n = 49) 
r 
Symptom duration -0.26 




Initial pain score 0.41 " 0.31 
Initial frequency score -0.14 -0.14 
Initial constipation score -0.18 -0.20 
Initial global score 0.17 0.07 
Anxiety 
VAS 0.05 -0.02 
Questionnaire 0.07 -0.01 
Depression 
VAS 0.08 0.01 
Questionnaire -0.06 -0.05 
r = product- moment correlation coefficient 
R = Spearman coefficient of rank correlation 
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** p < 0.01 
* p < 0.05 
Results and Analysis 
Table 8. Association between the change in frequency 
score and initial parameters. (n = 49) 
Symptom duration 
Fibre intake 









Initial frequency score 0.67 "' 0.54 "' 
Initial constipation score 0.54 "' 0.44 " 
Initial global score -0.20 -0.31 
Anxiety 
VAS 0.01 -0.02 
Questionnaire -0.14 -0.07 
Depression 
VAS -0.02 0.02 
Questionnaire -0.10 -0.15 
r = product- moment correlation coefficient 
R = Spearman coefficient of rank correlation 
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*** p < 0.001 
** p < 0.01 
Results and Analysis 
Table 9. Association between the change in constipation 
score and initial parameters. (n = 49) 
Symptom duration 
Fibre intake 









Initial frequency score 0.60 "' 0.48 " 
Initial constipation score 0.67 "' 0.63 "' 
Initial global score -0.20 -0.34 ' 
Anxiety 
VAS 0.12 0.13 
Questionnaire -0.07 0.03 
Depression 
VAS -0.05 0.00 
Questionnaire -0.08 -0.13 
r = product- moment correlation coefficient *** p < 0.001 
R = Spearman coefficient of rank correlation ** p < 0.01 
* p < 0.05 
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Results and Analysis 
Table 10. Association between the change in global score 
and initial parameters. (n = 49) 
r R 
Symptom duration 0.11 0.00 
Fibre intake 0.01 -0.02 
Initial pain score -0.23 -0.20 
Initial frequency score -0.13 -0.02 
Initial constipation score -0.12 -0.06 
Initial global score 0.30 0.27 
Anxiety 
VAS -0.24 -0.14 
Questionnaire -0.24 -0.18 
Depression 
VAS -0.21 -0.15 
Questionnaire -0.27 -0.17 
r = product- moment correlation coefficient not significant 
R = Spearman coefficient of rank correlation 
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Results and Analysis 
Assessment of outcome 
For the purposes of the subsequent analysis the 28 subjects who reported 
'improvement' make up one group. The 15 subjects who reported either no 
change in symptoms at the end of the study (8), or withdrew because of 
poor symptom response (4) or exacerbation of symptoms (3), constitute the 
other group, designated not improved. 
After three months the outcome whether measured objectively or by overall 
subjective evaluation, was independant of symptom duration and initial 
symptom scores [Table 11]. 
There was a significantly greater reduction in global colonic score in those 
patients who reported subjective improvement, but this was not accompanied 
by any change in the objective assessment of bowel habit [Table 12]. The 
reduction in global score reflected a reduction in pain score but the pain 
score change was not of sufficient magnitude to account for the whole global 
score change - the difference seems to reflect changes in other elements 
within the global scoring system. 
This may reflect genuine changes in these parameters. An alternative 
explanation is that the score accorded to these factors is modulated to a 
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greater degree by other factors in the complex process by which patients 
perceive, evaluate, and attribute symptoms. 
The pain score is a relatively crude method of analysing the pain of IBS 
which varies in intensity, site and character. Further, it has been known for 
decades that perception and reporting of pain is much influenced by 
psychological variables (Livingston 1953), and pain is a common symptom in 
psychiatric outpatients (Mersky and Spear 1967). 
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Results and Analysis 
Table 11. Comparison of Improved and Not Improved Groups. 
(mean scores) 
Symptom duration (years) 






















Initial pain score 6.0 7.1 1.1 1.7 0.7 
range 0 - 16 7 - 31 
Initial frequency score 10.2 13.0 2.8 2.4 1.2 
range 4 - 30 2 - 28 
Initial constipation score 31.3 43.0 12.7 10.2 1.2 
range 6 - 130 3 - 141 
Initial global score 7.4 7.1 0.3 0.7 0.5 
range 2 - 11 4 - 12 
not significant 
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Results and Analysis 
Table 12. Association between the reduction in symptom scores 






Diff SED t 
Pain 2.6 0.5 2.1 1.4 1.5 
range -1 - 10 -3 - -5 
Frequency 1.0 0.3 0.7 1.6 0.4 
range -2 - 9 -4 - 11 
Constipation 4.0 -2.4 6.4 6.3 1.0 
range -10 - 52 -8 - 32 
Global 4.6 1.6 3.0 0.8 4.0 - 
range 0 - 8 -2 - 7 
** p < 0.01 
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Results and Analysis 
Effect of treatment 
The treatment groups did not differ in any of the examined parameters which 
were considered likely influences on outcome [Table 13]. After three months 
the outcome in both groups, was independant of treatment group [Table 14]. 
There was no difference in the proportion of subjects who reported feeling 
'generally better' ; 59 per cent (fibre supplemented) vs 70 per cent (placebo) 
[Table 15]. Nor was there any significant difference in the initial changes in 
specific IBS symptoms between the groups [Tables 16 - 19]. The inter- 
relationship between the reduction in symptom scores, treatment, initial 
symptom scores, and psychometric assessment is examined in Tables 20 - 
23. 
Although some studies have shown symptomatic improvement with fibre 
supplementation (Manning 1977, Prior et al 1987, Kumar et al 1987), a greater 
number have reported no significant advantage over placebo (Hillman et al 
1984, Soltoft et al 1976, Longstreth et al 1981, Arthurs 1983, Lucey 1987, 
Arffmann et al 1986). A consensus has developed that dietary fibre 
supplementation can reduce constipation but that it has little more than a 
placebo effect on the other symptoms which characterise IBS. 
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Our patients all had a long history of abdominal symptoms and none had 
previously taken bran supplements for a sustained period as treatment for 
their symptoms. This is a considerable exclusion, given that dietary 'fibre' is 
the treatment of first resort for most physicians when faced with a patient with 
a putative diagnosis of IBS /idiopathic constipation. The patients had similar 
daily fibre intake to that of the general population. Fibre intake was increased 
by approximately 20 per cent to around 25g / day in the treated group. This 
relatively small increment may account for the low incidence of reported side 
effects and low drop out rate. On the other hand, those patients who did not 
improve might have done so with a greater fibre supplementation than was 
practicable using this concentrated tablet formulation. 
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Results and Analysis 
Table 13. Treatment groups : Initial characteristics. (mean [SD]) 
Treatment Group A 
n = 25 
B 
n = 24 
sex ratio (male:female) 9 : 16 8 : 16 
age (years) 39.2 [13.0] 39.8 [13.0] 
range 18 -76 20 - 65 
daily fibre intake (g) 20.9 [6.6] 19.4 [4.9] 
range 7 - 31 10 -30 
symptom duration (years) 3.4 [3.3] 4.2 [4.9] 
range 0.25 - 10 0.25 - 11 
initial pain score 5.9 [5.1] 6.8 [5.1] 
range 0 - 18 0 -17 
initial frequency score 10.4 [6.5] 11.1 [8.2] 
range 2 - 30 3 -28 
initial constipation score 31.0 [23.1] 36.3 [38.7] 
range 3 - 141 4 - 108 
initial global score 7.4 [2.3] 7.1 [2.6] 
range 2 - 12 2 -11 
not significant 
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Results and Analysis 
Table 14. Effect of Treatment on Outcome ; objective 
measures of outcome (reduction in symptom 
scores between week 0 and week 12) 
Treatment group A B Diff SED t 
n=22 n=20 
Mean reduction in 
Pain score 1.4 2.4 -1.0 1.2 0.8 
range -2 - 6 -3 - 10 
Frequency score -0.1 1.5 -1.6 1.4 1.2 
range -2 - 11 -4 - 9 
Constipation score -3.1 6.8 -9.9 5.3 1.9 
range -10 - 32 -8 - 52 
Global score 3.0 3.8 -0.8 0.8 1.0 
range -2 - 8 -1 - 7 
not significant 
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Results and Analysis 
Table 15. Effect of Treatment on Outcome ; subjective self -evaluation of 
change between week 0 and week 12. 
Treatment group A B 
n=25 n=24 
Improved 13 14 
Not improved 9 6 
not significant 
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Results and Analysis 
Table 16. Comparison of Improved and Not Improved Groups in 
treatment group A ; initial characteristics. Mean scores 
Improved Not 
Improved 
Diff SED t 
Symptom duration (years) 
range 
Fibre intake (g /day) 
range 
n = 13 
3.2 
0.25 - 7 
19.4 
7 -27 
n = 9 
4.3 









Initial pain score 4.5 8.0 3.5 2.2 1.2 
range 0 - 12 2 - 18 
Initial frequency score 8.8 13.2 4.4 2.8 1.6 
range 2 - 70 5 - 62 
Initial constipation score 24.2 42.1 17.0 9.7 1.9 
range 3 - 119 12 - 141 
Initial global score 7.2 6.7 0.5 1.1 0.5 
range 3 - 12 2 - 11 
not significant 
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Results and Analysis 
Table 17. Comparison of Improved and Not Improved Groups in treatment 
group A ; reduction in symptom scores. (mean) 




n = 13 
1.5 
-1 - 6 
n = 9 
1.0 
-2 - 5 
0.5 1.8 0.3 
frequency score -1.0 1.2 -2.2 1.8 1.2 
range -2 - 8 -1 - 11 
constipation score -4.2 -1.2 -2.3 5.1 0.5 
range -10 - 20 -8 - 32 
global score 4.5 0.9 3.6 0.9 3.9 
range 0 - 8 -2 - 6 
*** p < 0.001 
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- 
Results and Analysis 
Table 18. Comparison of Improved and Not Improved Groups in 
treatment group B ; initial characteristics. (mean) 
Improved Not 
Improved 
Diff SED t 
n = 14 n = 6 
Symptom duration (years) 4.5 3.0 1.5 2.5 0.6 
range 0.25 - 12 1 - 6 
Fibre intake (g /day) 18.6 23.0 4.4 3.2 1.4 
range 10 - 26 12 - 30 
Initial pain score 7.5 5.6 1.9 2.6 0.7 
range 2 - 26 0 - 15 
Initial frequency score 11.5 12.6 1.1 4.2 1.3 
range 4 -21 3 -28 
Initial constipation score 36.5 44.6 8.1 20.1 0.4 
range 4 - 108 8 - 82 
Initial global score 7.6 7.8 0.2 0.8 0.2 
range 2 - 9 4 -11 
not significant 
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Results and Analysis 
Table 19. Comparison of Improved and Not Improved Groups in 
treatment group B ; reduction in symptom scores. (mean) 
Improved 
n = 14 
Not 
Improved 
n = 6 
Diff SED t 
pain score 3.7 -0.4 4.1 2.2 1.9 
range 0 - 10 -3 - 4 
frequency score 0.8 -1.4 4.2 2.8 1.5 
range -2 - 9 -4 - 4 
constipation score 11.6 -3.4 15.0 12.1 1.2 
range 4 - 52 -8 - 22 
global score 4.6 2.8 1.8 1.3 1.5 
range 0 - 6 -1 - 7 
not significant 
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Results and Analysis 
Table 20. Association between the reduction in pain score and initial 
parameters [According to treatment groups]. 
r R 








Symptom duration -0.31 -0.36 -0.30 -0.33 
Fibre intake -0.24 -0.18 -0.15 0.02 
Initial pain score 0.23 0.66 " 0.16 0.41 
Initial frequency score -0.40 0.08 -0.47 0.21 
Initial constipation score -0.49 0.04 -0.68 " 0.22 
Initial global score 0.18 0.23 0.12 0.07 
Anxiety 
VAS -0.42 -0.54 -0.30 0.16 
Questionnaire -0.37 -0.49 -0.03 -0.31 
Depression 
VAS -0.35 -0.62 -0.27 0.45 
Questionnaire -0.40 -0.5V -0.30 -0.19 
r = product- moment correlation coefficient 
R = Spearman coefficient of rank correlation 
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** p < 0.01 
* p < 0.05 
Results and Analysis 
Table 21. Association between the reduction in frequency score and initial 
parameters [According to treatment groups]. 
r R 








Symptom duration 0.00 0.19 -0.07 0.21 
Fibre intake -0.21 0.11 -0.03 0.19 
Initial pain score 0.31 -0.17 -0.03 -0.10 
Initial frequency score 0.68 " 0.68 " 0.66 " 0.55 
Initial constipation score 0.39 0.61 " 0.45 0.54 
Initial global score -0.27 -0.25 -0.39 -0.28 
Anxiety 
VAS -0.10 0.35 -0.10 0.12 
Questionnaire -0.16 0.29 0.09 0.13 
Depression 
VAS 0.03 -0.05 -0.02 0.11 
Questionnaire 0.15 0.01 -0.19 0.22 
r = product- moment correlation coefficient 
R = Spearman coefficient of rank correlation 
122 
** p < 0.01 
* p < 0.05 
Results and Analysis 
Table 22. Association between the reduction in constipation score initial 
parameters [According to treatment groups]. 
r R 








Symptom duration -0.19 0.35 -0.28 0.48 
Fibre intake 0.02 0.16 -0.04 0.24 
Initial pain score -0.27 -0.17 -0.49 ' -0.04 
Initial frequency score 0.26 0.77 "' 0.07 0.82 "' 
Initial constipation score 0.49 ' 0.74 "' 0.38 0.81 "' 
Initial global score -0.35 -0.27 -0.34 -0.37 
Anxiety 
VAS -0.19 0.15 0.11 0.20 
Questionnaire 0.08 0.21 -0.12 0.31 
Depression 
VAS 0.22 -0.28 0.15 -0.10 
Questionnaire 0.19 0.07 0.22 0.03 
r = product- moment correlation coefficient 
R = Spearman coefficient of rank correlation 
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*** p < 0.001 
* p < 0.05 
Results and Analysis 
Table 23. Association between the reduction in global score and initial 
parameters [According to treatment groups]. 
r R 
Treatment group A 
n = 22 
B 





Symptom duration -0.14 0.17 -0.24 0.09 
Fibre intake -0.56 0.39 -0.53 0.42 
Initial pain score -0.13 -0.03 -0.11 -0.11 
Initial frequency score -0.32 0.32 -0.27 0.54 ' 
Initial constipation score -0.29 0.25 -0.40 0.40 
Initial global score 0.29 0.13 0.22 0.18 
Anxiety 
VAS -0.49 0.01 -0.43 0.16 
Questionnaire -0.31 -0.12 -0.27 0.19 
Depression 
VAS -0.16 -0.14 -0.15 -0.06 
Questionnaire -0.21 0.09 0.06 -0.12 
r = product- moment correlation coefficient * p < 
0.05 
R = Spearman coefficient of rank correlation 
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Results and Analysis 
Outcome and psychometric score 
Those subjects who felt 'generally better' after treatment had scored 
significantly lower in the initial assessments of depression than the other 
subjects. There was a trend towards lower scores in the assessments of 
anxiety in those who felt 'generally better' but this did not reach conventional 
levels of significance [Table 24]. 
The treatment groups were very similar in terms of psychometric scores 
[Table 25]. 
Initial depression ratings were a better predictor of improvement during the 
study period than any of the other parameters including inclusion in the fibre 
supplemented group. 
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Results and Analysis 
Table 24. Outcome and Psychometric Score. (mean) 
Improved Not improved 
n =22 n =20 
Anxiety 
Diff SED t 
VAS 34.9 43.3 8.4 4.7 1.78 
range 11 - 89 16 - 89 
Questionnaire 1.4 2.5 1.1 0.5 1.99 
range 0 - 9 0 - 9 
Depression 
VAS 26.2 35.6 9.4 3.9 2.43 ' 
range 14 - 70 4 - 67 
Questionnaire 0.7 2.6 1.9 3.8 2.86 " 
range 0 - 5 0 - 4 
** p < 0.01 
* p < 0.05 
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Results and Analysis 
Table 25. Initial psychometric scores according to treatment 




VAS 41.6 [18.1] 36.3 [15.0] 
range 14 - 67 11 - 89 
Questionnaire 1.9 [1.8] 1.7 [1.5] 
range 0 -5 0 -7 
Depression 
VAS 30.6 [16.4] 31.0 [11.7] 
range 11 - 49 4 -70 
Questionnaire 1.2 [1.9] 0.9 [1.6] 
range 0 - 3 0 -5 
not significant 
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Results and Analysis 
Table 26. Comparison of Improved and Not Improved Groups in treatment 
group A ; initial psychometric scores. (mean) 
Improved Not Diff SED t 
Improved 
Anxiety 
n = 13 n = 9 
VAS 34.5 48.9 14.4 7.5 1.9 
range 14 - 67 25 - 89 
Questionnaire 1.7 2.4 0.7 0.8 1.1 
range 0 -4 0 -5 
Depression 
VAS 24.7 39.7 15.0 6.0 2.2 ' 
range 14 - 49 11 - 47 
Questionnaire 1.1 1.4 0.3 0.6 2.0 
range 0 -3 0 -3 
* p < 0.05 
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Results and Analysis 
Table 27. Comparison of Improved and Not Improved Groups in treatment 
group B ; initial psychometric scores. (mean) 







n = 14 
39.4 
11 - 89 
1.8 
1 - 6 
n = 6 
33.5 
16 - 70 
2.0 








VAS 30.8 28.3 2.5 6.0 0.4 
range 16 -70 4 -67 
Questionnaire 1.0 0.7 0.3 0.3 0.9 
range 0 -5 0 -4 
not significant 
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The study population was a cohort of 75 consecutive patients referred to a 
gastrointestinal outpatient clinic, diagnosed as suffering from irritable bowel 
syndrome and recruited over a three month period, five years previously. 
Diagnosis 
The diagnosis was made on the basis of an altered bowel habit 
(unaccompanied by rectal bleeding) of at least three months duration, 
abdominal pain present most days and frequently relieved by defaecation, 
and abdominal distension, without symptoms of systemic upset. 
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Methodology 
Assessment : gastrointestinal symptoms 
At the initial assessment all patients completed a 34 item questionaire 
examining gastrointestinal symptoms. This was self administered and 
requested details of symptoms in the previous three months. At initial 
assessment answers to every question was obtained by, if necessary, further 
explanation to the patient. In the postal survey this was clearly not possible. 
Five years after the initial assessment patients were sent a postal 
questionnaire (using many of the same questions as the original 
questionnaire) which sought information on present symptoms and treatment, 
and on events since the diagnosis [Appendix 4]. A single telephone request 
for cooperation was made four weeks after postal contact if no reply had 
been received. 
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From the questionnaires symptom scores were calculated for; 
stool frequency (number of stools / week) 
straining at stool (range 0 -4) 
hard or pellety stool (range 0 -4) 
urgency to defaecation (range 0 -4) 
abdominal pain (range 0 -4) 
relief of pain with defaecation (range 0 -2) 
sensation of incomplete emptying (range 0 -4) 
Reported estimates of such bowel and gastrointestinal functions show 
reasonable correlation with detailed calendar diaries of bowel habit (Manning 
et al 1976). 
Assessment : general well -being 
An overall assessment of well -being was also sought; 
'How is your tummy trouble now compared to when you first 
attended this hospital ?' 
Possible responses were 'unchanged', 'better' or 'worse'. 
Use of medications 
Details were sought regarding the use of prescribed medications, of self 




A modified Middlesex Hospital Questionnaire was used to assess 
psychological status. The questionnaire included the same items assessing 
depression and anxiety as had been used 5 years previously. The Crown 
Crisp Experiential Index (CCEI) is an objective and valid technique which 
gives information similar to that obtained by formal psychiatric assessment at 
interview, at least in terms of the likely psychiatric 'caseness' or diagnoses 
(Crown and Crisp 1979). In the initial study the full 48 item questionnaire was 
used. It was thought unlikely that subjects would respond to a postal 
questionnaire if it was 20 -30 pages long : therefore the number of individual 
questions was minimised. 
In the previous study only those questions examining phobic anxiety, free 
floating anxiety, and depression were considered useful in differentiating 
between those with functional disorders and those with organic diagnoses. 
The follow -up questionnaire was restricted to the eight questions in each of 
these subsets : 
'FFA'. Anxiety without identifiable cause. 
'PHO' Anxiety which is limited to particular situations and which does 
not occur outwith those situations. 
134 
'DEP' Sadness of mood accompanied by psychomotor blunting 
or slowing. 
Each item scores 0 -2 and each subset therefore a total of 0 -16 [Appendix 5]. 
Only the FFA and DEP subsets are reported here. 
Psychological assessment 
Depression and anxiety were also assessed by a visual analogue scale. This 
method has been validated on a horiziontal linear model (Ingham 1965, 
Ingham and Miller 1976). 
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Results and Analysis 
Of the 75 patients studied originally, three had died of unrelated disease, and 
the whereabouts of 13 could not be traced. Of the remainder, 43 patients 
(73 %), returned completed questionnaires. 16 patients failed to respond to a 
second postal invitation and /or a telephone request. 
The characteristics of the respondents are shown in Table 28. Those patients 
who did not reply to the five year follow -up questionnaire were not 
significantly different from the respondents in the following parameters at 
initial assessment ; age, duration of symptoms, severity of initial symptoms, 
or initial anxiety and depression ratings. 
Outcome 
28 patients (65 %) reported that their 'tummy trouble was better than when 
first seen at the clinic', 13 (30 %) reported 'unchanged', and 2 (5 %) 'worse'. 
The only gastrointestinal symptom which showed a significant correlation with 
overall assessment was pain; those patients who felt their 'tummy trouble was 
better' had significantly lower pain scores five years after initial referral. There 
was no similar correlation between the overall assessment and other 
gastrointestinal symptoms (initial or five year absolute levels or the change 
over the period) [Tables 29 & 30]. 
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Results and Analysis 







sex ratio (f : m ) 27 : 16 18:10 9 : 7 
enhanced dietary fibre at 27 [63 %] 20 [74 %] 7 [46 %] 
five years 
symptom duration (months) 50.1 (61) 42.1 (59) 66.0 (62) 
range 3 - 240 3 - 240 6 - 240 
age (years) 39.2 (10.9) 39.7 (11.2) 38.3 (10.5) 
range 18 - 60 18 - 60 24 - 59 
not significant 
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Results and Analysis 
Table 29. Relationship between outcome and initial 










1 - 30 
straining at stool 1.7 (1.5) 1.5 (1.1) 
range 0 - 4 0 -4 
hard or pellety stool 1.6 (1.6) 1.4 (1.2) 
range 0 - 4 0 -4 
urgency to defaecation 1.8 (1.4) 1.5 (1.6) 
range 0 - 4 0 -4 
abdominal pain 2.5 (1.4) 2.3 (1.2) 
range 0 - 4 0 -4 
relief of pain at defaecation 1.3 (0.8) 1.1 (0.8) 
range 0 - 2 0 -2 
sensation incomplete emptying 2.0 (1.4) 1.6 (1.1) 
range 0 - 4 0 -4 
not significant 
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Results and Analysis 
Table 30. Relationship between outcome and gastrointestinal symptom 





stool frequency [per week] 9.6 (6.7) 11.5 (7.7) 
straining at stool 1.1 (1.0) 1.4 (1.2) 
range 0 -4 0 -4 
hard or pellety stool 1.1 (1.3) 1.5 (1.9) 
range 0 -4 0 -4 
urgency to defaecation 1.5 (1.2) 1.4 (1.4) 
range 0 -4 0 -4 
abdominal pain 1.3 (1.1) 2.3 (1.6) " 
range 0 -4 0 -4 
abdominal pain : change -1.2 (1.7) -0.1 (1.5) " 
range -4 - +1 -2 - +2 
relief of pain at defaecation 1.4 (0.8) 1.1 (0.7) 
range 0 -2 0 -2 
sensation incomplete emptying 1.6 (1.3) 2.1 (1.3) 
range 0 -4 0 -4 
** p < 0.01 
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Results and Analysis 
The relationship between anxiety scores and five -year general outcome is 
shown in Table 31. The trend was clearly for those patients who reported 
feeling 'better' to record lower scores at initial assessment and at the five year 
reassessment than those who reported feeling 'unchanged' or 'worse'. 
However, the difference between the outcome groups did not achieve 
statistical significance at the conventional p < 0.05 level. 
In both groups there was a trend to reduced anxiety scores after the five year 
interval but in neither group was this change significant, and the magnitude 
was similar in the groups [Table 31]. 
There was no difference in initial or five year depression scores between 
those patients who were 'better' and those who were not [Table 31]. 
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Results and Analysis 
Table 31. Relationship between outcome and scores for 
anxiety and depression. (mean) 
initial anxiety 
range 














range 0 - 12 0 - 13 
initial depression 4.6 5.5 0.62 
range 0 - 10 2 - 12 
five year depression 3.3 3.7 0.55 
range 0 - 10 2 - 7 
(Mann Whitney U test) 
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Results and Analysis 
Medications 
53% of patients were taking no regular medications. No patients were taking 
medications for other complaints. In the 22 patients (47 per cent) taking 
prescribed treatment (other than laxatives) each week for gastrointestinal 
symptoms, mebeverine was the drug used most often. Seven patients were 
taking more than one medication on a regular basis. Five patients (12 per 
cent) were taking 'bulking' laxatives regularly. No other laxatives were being 
used. A single patient reported taking a tranquilliser. There was no difference 
between the outcome groups in the use of medications. 
Three patients had had treatment for 'nerves'. 77 per cent of patients thought 
that 'worry or nerves usually upset their tummy trouble'. One patient had 
found meditation of help. Only one other 'alternative' approach had been tried 
one patient reported no effect of herbalism (other treatments had likewise 
failed to effect an improvement). 
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Analysis and Results 
Dietary Fibre 
63 per cent of patients had increased their dietary fibre intake in an effort to 
reduce their symptoms, and were persisting with that change. No patients 
reported that they avoided specific foodstuffs, but one reported that alcohol 
exacerbated her symptoms. Two patients had been referred in the intervening 
years to another clinic with the same symptoms ; in both cases the diagnosis 
(as reported by the patient) was unchanged. 
Clinic visit 
Eight patients (19 per cent) thought that the gastrointestinal clinic visit and the 
treatment and advice they had received had been of no help, six (14 per 
cent) judged it completely helpful, and 29 (67 per cent) partially helpful. These 
groups did not differ in respect of age, initial gastrointestinal symptoms, or in 
the initial or five year anxiety and depression ratings. The duration of 
symptoms in these groups were 30.3 months, 65.3 months and 11.3 months 
respectively. 
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Analysis and Results 
This study confirms the persistence of troublesome GI symptomatology in a 
substantial minority (here 35 per cent) of IBS patients. No alternative 
diagnosis had emerged during the five year follow -up, attesting the accuracy 
of the initial diagnosis. The majority of respondents continued to adhere to a 
high fibre diet. At the time of the initial visit our standard approach to patients 
with patients with IBS was to recommend a high fibre diet after a detailed 
explanation of the condition, emphasising the benign long -term course and 





A biochemical parameter which afforded an objective measure of the 
emotional response to 'stress', or which reflected the degree of anxiety or 
depression engendered, would clearly be of great value. Previous attempts 
to find such a parameter have been disappointing, making little impact on 
routine assessment. Review of the literature revealed several possible 
candidates but many had drawbacks which would have made their use in 
routine clinical practice impossible, at least in the foreseeable future. I was 
concerned to investigate parameters which might prove a practical, reliable 
guide to psychological components of the IBS symptom complex. 
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Salivary IgA estimation. 
Bartrop et al (1977) were first to demonstrate that emotional state might 
influence aspects of immunocompetence. In bereaved subjects there was 
reduced lymphocyte response to mitogens, although there was no difference 
in lymphocyte numbers, immunoglobulin concentrations, autoantibody profiles, 
or plasma cortisol levels. Severe depression can diminish components of the 
immune response (Schleifer et al 1985 , Kronfol et al 1983). 
Academic stress is reported to cause several changes in immunocompetence; 
1. Mitogen responsiveness of lymphocytes is reduced (Dorian et al 1982). 
2. T helper -cell proportion is increased (Baker et al 1985). 
3. Salivary secretory immunoglobulin A (slgA) production is enhanced. 
Jemmott et al (1983) reported that the rate of salivary IgA production 
might be reduced by academic stress, a phenomenon which was 
modulated by personality factors. 
Salivary IgA concentration is probably inversely related to flow rate, and the 
rate of saliva production is clearly influenced by mood ; witness the dry 
mouth of extreme fright or acute anxiety. Stone et al (1987) have argued that 
mood -related modulation of salivary IgA production is therefore a poor 
measure of immune function. 
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However it was not the purpose of this study to advance this arguement ; 
rather I sought to establish whether salivary IgA might be a clinically useful 
measure of mood or response to stress in IBS patients. 
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Methodology 
Saliva collection and analysis 
Saliva samples were collected as follows : 
Specimens were collected between one and four pm from seated, rested, 
subjects who were alone in the examination room. Subjects had not eaten or 
drunk anything, smoked, or cleaned their teeth, in the hour before collection, 
and were asked not to cough prior to spitting. 
Subjects with infection or ulceration of the mouth, or with active dental caries 
or gum disease (of greater than clinically mild severity) were excluded. 
Subjects spat unstimulated saliva into a universal container for 5 minutes. The 
whole saliva was quantified using a 20m1 syringe which was also used to 
transfer it into a 10 ml stoppered plastic or glass tube such as is used for 
clotted blood specimens. 
The specimen was immediately frozen and stored at 4 °C. 
Salivary IgA was subsequently assessed by immunoturbidimetry on a 
Monarch centrifugal fast analyser (adapted from Wenham and Horn 1980). 
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Methodology 
Blood collection and analysis 
Immediately after collection of the saliva a 20 ml sample of venous blood was 
drawn from the relaxed subjects' antecubital fossa, using a tourniquet. Serum 
IgA levels were likewise assayed by immunoturbidimetry (Wenham and Horn 
1980) . 
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Results and Analysis 
There was no correlation between salivary IgA concentration or its' rate of 
production and the salivary amylase or Na concentration [Table 34]. Salivary 
IgA and its' rate of production was similar in IBS patients to that found in the 
general population. As in previous reports there was no correlation between 
serum and salivary IgA (Finkelstein et al 1984) [Table 33]. There was no 
correlation with the measures of stress (anxiety and depression) used in this 
study [Table 36 & 38]. It therefore seems unlikely that salivary IgA will be 
useful in identifying those IBS sufferers in whom such anxiety and /or 
depression are predominant determinants of the sickness behaviour. Further 
studies may permit correlation between the rate of salivary IgA production 
and initial symptom assessments. 
I have no ready explanation for the relationship between salivary IgA 
concentration and bowel habit [Table 37]. The salivary IgA concentration is 
increased as the bowel habit is less constipated (frequency and constipation 
scores increase). This may indicate an undefined correlation between bowel 
habit and salivary IgA but may equally represent a chance finding - there is 
no correlation with the rate of IgA production [Table 35]. 
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Results and Analysis 
Table 32. Serum and Salivary IgA. (n = 49) 
mean range SD 
Salivary IgA IU / ml 7.25 2.0 - 21.2 2.3 
Salivary IgA IU / min 3.4 0.5 - 10.7 2.1 
Serum IgA iu / ml 126 44 - 246 52 
Table 33. Association between serum and salivary IgA. (n = 49) 
r R 
salivary IgA concentration -0.12 -0.15 
salivary IgA production rate 0.01 0.00 
Table 34. Association between IgA and other salivary constituents. 
(n = 49) 
salivary Na 
salivary amylase 
r = product- moment correlation coefficient 






Results and Analysis 
Table 35. Relation between Salivary IgA production rate [lU / min] 
and symptoms. (n = 49) 
initial pain score 
initial frequency score 
initial constipation score 
initial global score 
change in pain score 
change in frequency score 
change in constipation score 










r = product- moment correlation coefficient 
R = Spearman coefficient of rank correlation 
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not significant 
Results and Analysis 
Table 36. Relation between Salivary IgA production rate [lu / min] and 
psychometric assessment. (n = 49) 
Anxiety 
r R 
VAS -0.08 -0.11 
Questionnaire 0.17 0.12 
Depression 
VAS 0.01 0.09 
Questionnaire -0.09 0.01 
r = product- moment correlation coefficient 
R = Spearman coefficient of rank correlation 
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not significant 
Results and Analysis 
Table 37. Relation between Salivary IgA concentration [lU / ml] and 
symptoms. (n = 49) 
r R 
initial pain score -0.18 -0.15 
initial frequency score 0.37 0.21 
initial constipation score 0.43 " 0.37 
initial global score -0.23 -0.31 
change in pain score -0.05 0.01 
change in frequency score 0.59 "' 0.40 
change in constipation score 0.73 "' 0.38 
change in global score -0.01 -0.08 
r = product- moment correlation coefficient *** p < 0.001 
R = Spearman coefficient of rank correlation ** p < 0.01 
* p < 0.05 
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Results and Analysis 
Table 38. Relation between Salivary IgA concentration (lU / ml] and 
psychometric assessment. (n = 49)) 
Anxiety 
r R 
VAS 0.08 -0.02 
Questionnaire -0.10 -0.03 
Depression 
VAS 0.10 0.16 
Questionnaire -0.15 -0.18 
r = product- moment correlation coefficient 
R = Spearman coefficient of rank correlation 
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not significant 
Results and Analysis 
Table 39. Relationship between Salivary IgA and general outcome. 
(mean) 
Improved Not improved Diff SED t 
n =22 n =20 
Salivary IgA (IU / ml) 77.7 69.2 8.5 10.4 0.8 
range 31 - 212 10 - 84 
Salivary IgA (IU / min) 41.0 35.6 5.4 8.0 0.7 




The sympathetic nervous system is one pathway via which psychological 
influences on physiological function might be mediated. It is now generally 
accepted that urinary adrenaline is elevated by various mental stresses, and 
seems to correlate with subjective feelings of distress (Frankhauser 1975, 
Baum et al 1985). Noradrenaline is more sensitive to posture and exercise. 
Among the most potent stressors are anticipation of threat and emotional 
challenge (Johanssen et al 1983). 
Since plasma catecholamines are unaffected by excretory processes and 
renal function, they are thought by some to reflect sympathetic output more 
accurately than urinary catecholamines. However there are several important 
confounding factors ; 
1. the influence of drugs, exercise, beverages, posture, circadian rhythm, 
menstrual cycle, and age (Christensen 1983). 
2. the collection and storage of samples can introduce significant errors 
(Carruthers et al 1970) 
3. the half lives of adrenaline and noradrenaline are 12 minutes only and 
hence reflect very short term responses. 
4. assays on antecubital blood estimates predominantly forearm -tissue - 
derived catecholamine. This is much influenced by exercise and as the 
plasma adrenaline concentration increases with stress, so too does 
adrenaline extraction across the forearm (Jorgensen et al 1985). 
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For these reasons it was considered extremely unlikely that plasma 
catecholamines could possibly represent a rapid, practical, routine assessment 
of the level of anxiety / depression. 
Methodological difficulties also dog the routine use of urinary catecholamines 
in clinical practice (Ward and Mefford 1985) : 
1. consumption of coffee and alcohol, smoking, and medication may 
influence catecholamine levels in blood and urine. 
2. with stress the compartmentalisation of catecholamines may change, 
influencing urinary concentrations obtained. 
3. changes in catecholamines can be very rapid and may reflect short 
term emotional states. 
4. renal function can interfere with urinary catecholamines. 
Although it seems that urinary excretion mirrors the circulating levels 
of adrenaline and noradrenaline the influence of renal function has not 
been fully assessed. The renal nerves are a potential confounding 
source of noradrenaline (in dogs urinary noradrenaline is arterial 
plasma- derived (Kopp et al 1983). 
I did however study urinary catecholamine in the first 15 patients in the 
therapeutic trial and examined the relationship between this parameter, 




24 hour volumes of urine were collected from 15 patients who were subjects 
of the fibre supplementation study, before the treatment was commenced. 
The importance of complete collection was emphasised. Patients were 
excluded if they complained of specific urinary or genitourinary symptoms or 
if there was any history of flushing, hypertension, kidney stones or renal 
impairment. 
Urinary free metanephrine was assayed by radioimmunoassay. 
Results and Analysis 
There is a poor correlation between 24 -hour urinary metanephrines and 
VAS and questionnaire assessments of anxiety and depression. [Table 43] 
Perhaps the assessment would have been better performed before 
enrollment into the trial. The process of enrollment included some 
explanation of IBS, in order that informed consent be obtained, and this 
may have ameliorated some of the arousal associated with anxiety. In any 
event catecholamines may reflect shorter term emotional states of arousal 
and /or worry than those which are concerned in the development and 
maintenance of IBS. 
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Results and Analysis 
The patients were representative of those from the clinical trial cohort as a 
whole. 
Table 40. Subjects : Initial characteristics. (n = 10) 
mean range 
age (years) 36 20 - 64 
sex ratio (male:female) 9 : 6 
daily fibre intake (g) 18.9 12 - 28 




global symptom score 
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5.6 4 - 14 
12.2 3 - 24 
28.6 7 - 112 
6.9 2 - 11 
Results and Analysis 
Table 41. Urinary free metanephrine (ug / 24 hours). 
n mean range SD 
overall 15 2.26 1.34 - 3.3 0.86 
improved 9 2.17 1.34 - 2.9 0.72 
not improved 6 2.93 1.45 - 3.3 0.78 
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Results and Analysis 
Table 42. Correlation between urinary metanephrine and 
gastrointestinal symptoms. (n = 15) 
initial pain score 
initial frequency score 
initial constipation score 
initial global score 
change in pain score 
change in frequency score 
change in constipation score 










r = product- moment correlation coefficient not significant 
R = Spearman coefficient of rank correlation 
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Results and Analysis 
Table 43. Correlation between urinary metanephrine and psychometric 
scores. (n = 15) 
anxiety 
r R 




VAS 0.29 0.20 
Questionnaire 0.40 0.39 
r = product- moment correlation coefficient not significant 
R = Spearman coefficient of rank correlation 
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Serotonin 
The physiological role of serotonin has been the subject of much scrutiny 
and speculation. That serum contained a vasoactive substance was known 
for many decades before Rapport et al (1948) isolated the substance, and 
identified it as 5- hydroxytryptamine [3- (- aminoethyl) -5- hydroxyindole] 
(serotonin). Most of the bodies' serotonin is found in the enterochromaffin 
cells of the gastrointestinal tract (Erspamer 1954). It is synthesised by 
hydroxylation and decarboxylation of tryptophan in situ, as is the serotonin 
in most tissues. Within the enterochromaffin cells serotonin has a half life of 
approximately 15 hours. Release of serotonin into the intestinal circulation 
and into the gut lumen is increased by several factors ; mechanical 
stimulation, hypertonicity, feeding (Ferrara et al 1984), acidity, norepinephrine, 
and vagal influences (Ahlman et al 1981). The serotonin released into the 
enteric circulation is rapidly cleared from the plasma by uptake and 
degradation by endothelial cells, notably in the liver and lungs and by platelet 
uptake. However it seems that a relatively small proportion of gut 5 -HT is 
taken up by platelets (Anderson et al 1985). The physiological significance of 
serotonin in the gastrointestinal tract is still not fully understood. 
Circulating serotonin is almost all contained in the platelets, though perhaps 
20 per cent is bound to plasma protein (Demet et al 1978). Within the 
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platelets serotonin is stored in one of the three platelet granule types, the 
osmophillic dense granules ; the mechanism by which it is pumped into the 
granule is similar to that for catecholamines. Most, if not all, of this platelet - 
granule -bound serotonin is thought to originate in the enterochromaffin cells, 
platelets themselves being unable to synthesise serotonin. 
Platelets take up serotonin during passage through the enteric vessels by 
way of a high affinity, active uptake mechanism. This system is similar to that 
found in trytaminergic nerve endings which allows re- uptake of released 
transmitter. The turnover of serotonin in platelets is relatively slow with a half 
life of several days (Heysell 1961). 
The physiological effects of serotonin are often variable. This variability reflects 
the reflex, and therefore conditional, nature of many of the effects, and 
tachyphylaxis, which is common in serotonin mediated changes. The wide 
range of susceptibility to blocking agents points to the existence of several 
different serotonin receptors. Among the physiological effects of serotonin 
which have been demonstrated are ; 
1. The induction of platelet aggregation (Laubscher and Pletscher 1979). 
The function of platelet serotonin remains unestablished. 
2. Vasoactive properties. Serotonin can cause both constriction 
and dilatation depending on the vascular bed involved, its 
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resting tone, and the concentration of serotonin. Similarly cardiac 
output may be increased or decreased. 
3. Gastrointestinal motility regulation. Small intestinal motility is stimulated 
by infusion of serotonin, while motility in the stomach and colon is 
reduced (Misiewicz et al 1966). Enterochromaffin cells also contain 
substance P and motilin, two other potent motility regulators. In 
carcinoid syndrome, with its characteristic diarrhoea, the small intestine 
is known to be hypermotile and the colon relatively quiescent. Further, 
cholera toxin is a potent serotonin releasing agent (Cassuto et al 1980). 
But in rats enteric motility is not effected by virtually denuding the 
intestine of serotonin by feeding a tryptophan free diet. Non -mucosal 
enteric 5 -HT, found in the enteric neurones (Feldberg and Toh 1953), 
is considered by some to be a local neurotransmitter (Gershon and 
Erde 1981). The role of serotonin in the normal control of motility is 
unestablished. 
4. Neurotransmission. Much of the interest in serotonin centred on its role 
in central nervous system (cns) transmission processes. Within the cns 
the cell bodies of serotoninergic neurones are found almost exclusively 
in the raphe nucleus of the brain stem. Cns serotonin is synthesised 
in situ. Circulating serotonin is thought to have few central effects as 
it penetrates the blood -brain barrier very poorly. However tryptophan 
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injections can cause increases in brain serotonin levels within an hour 
in animal models (Ternaux et al 1981). The concentration of cns 
serotonin may thus be regulated by diet through changes in 
tryptophan. Precursor availablility seems to limit the rate of 
neurotransmitter synthesis. Serotoninergic mechanisms have been 
implicated in pain perception, in sleep regulation, and in control of 
behaviour and arousal (particularly in affective disorders). Central 
control of temperature and blood pressure control are also influenced 
by serotonin. However the precise mechanisms by which serotonin 
influences such systems have not yet been elucidated. The handling 
of serotonin in platelets is similar to that in serotoninergic neurones 
(Todrick and Tait 1969). Platelets have been proposed as a model for 
the study of serotonin behaviour in and around such neurones 
(Pletscher 1978). 
Changes in platelet serotonin have been reported in depression (Le Quan 
Bui et al 1984), migraine (Hilton and Cummimgs 1980, Hannington 1978), 
carcinoid syndrome (Grahame -Smith 1977), cirrhosis, premenstrual tension, 
and hypertension (Bargava et al 1979, Mehta and Mehta 1981). 
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Methodology 
Estimation of serotonin. 
The estimation of serotonin in platelets avoids many of the pitfalls of 
measuring whole blood hydroxyindoles. Here difficulties in serotonin extraction 
can lead to erroneous results and HIM may also be included in the 
estimation (Stacey 1966). 
Platelet serotonin was assayed by high pressure liquid chromatography 
(Tagari et al 1984). [Appendix 6] 
Subjects 
In a pilot study, 16 subjects were drawn from the clinics and wards of the 
Gastrointestinal Unit. Demographic characteristics are shown in Table 44. The 
diagnoses were made on the basis of history and investigation which included 
radiology in pancreatitis (endoscopic retrograde pancreatography) and 
histology in inflammatory bowel disease and gastrointestinal tract malignancy. 
In all cases intermittent abdominal pain was a prominent feature. None of the 
patients had a history of hypertension or migraine. None were judged to be 
depressed at clinical interview by the single investigator and none had 
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evidence (clinical or biochemical) of chronic hepatic disorder. None were 
taking antidepressant medication. All were in a clinically stable condition when 
serotonin was assayed, unchanged over several days. Blood for the assays 
was drawn fron rested patients between 11.00 am and 15.00pm. 
Results and Analysis 
Although platelet serotonin has been postulated as a potentially useful 
biochemical parameter in several disease states the results we obtained 
did not suggest a consistent change in IBS [Tables 45 - 48], though in 
such a condition there may be a subset of patients in whom, for example, 
depression is prominent who might be so identified. It did not help 
differentiate between IBS and other causes of chronic gastrointestinal 
symptoms. I did not consider the it appropriate to extend this pilot work 
particularly given the technical difficulties in specimen collection and 
analysis. 
170 
Results and Analysis 
Table 44. Subject characteristics for serotonin study 
n age male : female 
Irritable bowel syndrome 4 22 - 66 2 : 2 
Inflammatory bowel disease 4 19 - 54 2 : 2 
Pancreatitis 3 33 - 56 2 : 1 
Malignant disease 5 52 - 56 2 : 3 
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Results and Analysis 
Table 45. Platelet Serotonin [nmol / I] 
n mean range SD 
Irritable bowel syndrome 4 2067 675 - 3312 1245 
Inflammatory bowel disease 4 4203 2468 - 6740 1828 
Pancreatitis 3 2789 1515 - 4455 1509 
Malignant disease 5 1417 243 - 2833 1208 
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Results and Analysis 
Table 46. Platelet Serotonin [nmol I I] 
Differences between the diagnostic groups. 
[1] [2] [3] 
p Student t -Test 
[4] 
Irritable bowel syndrome [1] 0.10 0.52 0.54 
Inflammatory bowel disease [2] 0.11 0.33 0.03 
Pancreatitis [3] 0.63 0.40 0.20 
Malignant disease [4] 0.29 0.06 0.39 
p Mann Whitney U Test 
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Results and Analysis 
Table 47. Platelet Serotonin [pmol / 108 platelets] 
n mean range SD 
Irritable bowel syndrome 4 433 153 - 658 262 
Inflammatory bowel disease 4 589 418 - 764 156 
Pancreatitis 3 835 115 - 1200 623 
Malignant disease 5 308 8 - 501 163 
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Results and Analysis 
Table 48. Platelet Serotonin [pmol I 10f platelets] 
Differences between the diagnostic groups. 
[1] [2] [3] [4] 
p Student t -Test 
Irritable bowel syndrome [1] 0.34 0.29 0.61 
Inflammatory bowel disease [2] 0.34 0.57 0.03 
Pancreatitis 
Malignant disease 
[3] 0.62 0.62 0.28 
[4] 0.55 0.03 0.39 
p Mann Whitney U Test 
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THE INFLUENCE OF ALCOHOL 
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Introduction 
Symptoms related to alcohol consumption are a common cause of referral to 
gastrointestinal clinics and such symptoms include abdominal pain and 
diarrhoea (Langman and Bell 1975). Yet the prevalence of alcohol related 
problems in IBS patients has been addressed infrequently. Health workers are 
notoriously inept at identifying or recognising alcohol related problems 
(Barrison et al 1980). One would expect that in gastrointestinal clinics the 
recognition of alcohol excess or alcoholism would be improved, and the 
diagnoses would have to be considered as an explanation for the symptom 
complex of IBS. Nonetheless it was appropriate to exclude a potential role for 
alcohol in the symptom complex, particularly given the association between 
the use of alcohol and psychological disturbance. 
The detection of excessive alcohol consumption and alcoholism rests on three 
main planks ; 
1. A careful assessment during routine history taking. 
In some circumstance this can be as effective, or even more 
effective, than questionnaires, whether these are observer or self - 
administered. Waterson and Murray -Lyon (1988) found that 
direct questioning about the usual alcohol consumption level and 
bingeing was more effective than a CAGE questionnaire in 
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identifying patients with excess alcohol consumption in the 
setting of an antenatal clinic. 
2. Laboratory parameters. 
Several biochemical indices are said to change with chronic 
alcohol consumption. The most commonly used in routine 
practice are mean cell volume (MCV) and gamma- glutamyl- 
transferase (GGT). Others include cholesterol and transferrin. 
Gamma GT is elevated in 60 -80% of 'alcoholics' (Rosalki and 
Rau 1972), but it can be elevated in many other disease states, 
and by several medications. 
Chick et al (1981) described a correlation between 
acknowledged alcohol intake and GTT, but a disappointing 
sensitivity of 54 %, and a false positive rate ranging from 10% to 
50% in his subject groups (there were three) when used to 
identify those with alcohol consumption greater than 450g / 
week (all his subjects were men). 
The sensitivity of MCV was even lower : 20 °/ - 40% in a study 
of 63 well nourished patients with an admitted alcohol intake of 
more than 80g / day (Wu et al 1974). He reported an MCV of 
greater than 90f1 in 89 %. In 29% of patients there was evidence 
of folate deficiency. 
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3. Specific interview techniques, largely standardised questionnaires. 
The questionnaires which are most commonly used originated 
in the USA and ask about drinking behaviour and alcohol 
associated problems, the quantity of alcohol being of lesser 
importance for these interview techniques. The Michigan 
Alcoholism Screening Test (MAST) is perhaps the best known 
(Selzer 1971). But it is somewhat cumbersome, with 24 items, 
and seen by some patients as threatening. The CAGE 
questionnaire is a simpler test, consisting of only four questions. 
[Appendix 7] Derived by Ewing and Rouse (Ewing 1984) during 
work in a general hospital setting, it has been validated and 
proved useful in this setting, in psychiatric inpatients (Mayfield 
et al 1974), in medical outpatients, and in primary care (Wallace 
and Haines 1985). 
CAGE has been criticised for identifying only heavy drinkers and 
for overdiagnosing those individuals who feel guilty about 
modest levels of alcohol intake. However Saunders and Kershaw 
(1980) found CAGE more sensitive than MAST in a community 
survey. 
There is dispute about the relative merits of self- administration vs 
physician administration of such questionnaires but it seems to have 
relatively little effect on sensitivity or specificity. 
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Bernadt et al (1982) found that the GTT did correlate with alcohol 
consumption, as did the MCV. In 385 patients admitted to a psychiatric 
hospital he compared the sensitivity of CAGE, MCV and GGT for detecting 
both alcoholism and excess alcohol consumption. 
Sensitivity (% in the category with an abnormal result) 
CAGE GTT MCV Diagnostic category 
91 33 2 Alcoholism 
93 36 0 Excess alcohol 
Specificity (% not in the category with a normal result) 
CAGE GTT MCV Diagnostic category 
77 87 99 Alcoholism 
76 87 99 Excess alcohol 
The MCV is a tool of very low sensitivity and is therefore of little use in the 
detection of alcohol related problems. GGT fails to detect two out of three of 
those with alcoholism or excess alcohol consumption. CAGE detects nine out 
of ten alcoholics or excess drinkers, but is abnormal in 25 per cent of those 
who are outwith these diagnostic categories. 
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Methodology. 
The clinical assessment of the 49 patients who comprised the therapeutic trial 
cohort included routine enquiry about alcohol intake and related problems. 
In addition the cage questionnaire was administered by the physician (in all 
cases myself). MCV and GGT were analysed on the baseline blood sample. 
Results and Analysis. 
No subjects scored more than two on the CAGE questionnaire. Three 
patients scored two, and seven one. The remaining patients scored zero. The 
dietician also enquired about alcohol in the 24 hour recall. In none of the 
recalls was the reported alcohol intake greater than one unit and the dietician 
commented on possible alcohol abuse in no patients. 
There was no correlation between GTT and MCV. [Table 49] Neither GGT, 
MCV, nor CAGE correlated with the clinical and psychometric assessments 
shown if Table 51. Nor was an association demonstrated between the 
parameters of alcohol consumption and general outcome. [Table 50] 
It seems that alcohol plays little part on IBS itself. However this is not to deny 
that gastrointestinal upsets secondary to alcohol intake can mimic the IBS 
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symptom complex. In the gastrointestinal outpatient clinic awareness of 
alcohol as a potential problem is high and the fact that none of the patients 
seemed to have alcohol related symptoms or problems is testimony to the 
vigorous exclusion of such patients from the IBS diagnostic category in 
routine clinical evaluation. 
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Results and Analysis 
Table 49. Biochemical parameters of alcohol intake. 
mean range SD r 
Gamma GT (IU /I) 20.9 
MCV (fl) 
2 - 54 9.59 
90.2 85 - 98 3.57 
p 
-0.13 0.50 
Table 50. Biochemical parameters of alcohol intake : relationship with overall 
outcome. (mean, range) 
better unchanged / worse 
n=22 n=20 
Gamma GT (IU /I) 21.7 (2 - 49) 20.2 (7 - 36) 
MCV (fl) 89.2 (85 - 98) 90.5 (87 - 97) 
not significant 
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Results and Analysis 
Table 51. Relationship between parameters of alcohol intake and 
clinical and psychometric assessments. (R) 
MCV (fl) GGT (IU /I) CAGE 
anxiety VAS 0.07 0.17 0.08 
questionnaire 0.10 0.11 0.18 
depression VAS 0.23 0.08 0.21 
questionnaire 








frequency -0.12 0.24 0.08 
constipation 0.08 -0.07 -0.28 
global 








frequency -0.06 -0.19 0.14 
constipation -0.15 0.07 -0.21 
global 0.03 0.11 0.09 
R = Spearman coefficient of rank correlation 
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not significant 
GENERAL PRACTITIONER CONSULTATIONS 
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As the initial co- actors in the doctor -patient relationship which modulates the 
future direction and content of the illness behaviour, general practitioners play 
a pivotal role in determining those patients who are referred to outpatient 
clinics. This process of selection has a large influence on the characteristics 
of the patients with a diagnosis of IBS who form the subjects for most studies 
of the syndrome. Many people who experience IBS 'symptoms' are not 
referred on by their general practitioner. Presumably within the context of their 
relationship both GP and patient are satisfied with the agreed explanation and 
'reattribution', such that the 'symptoms' are redesignated 'experiences'. 
The clinic or hospital doctor misses this all- important, scene -setting interaction 
and is henceforth disadvantaged in understanding the illness behaviour, 
having to rely on the face to face account of only one of the actors. Several 
factors which are considered to modulate consulting behaviour were beyond 
the scope of this study, but I was interested in whether attendance at an 
outpatient clinic had a effect on the temporal pattern of attendance or on the 
principal complaint noted in the GP record. Further I wished to establish 
whether any change in consulting behaviour was related to psychological 
scores at the outset or five years later, and to examine the relationship 




In order to assess the patient -general practitioner interaction which produced 
the hospital referral, the general practitioner medical records of 20 of the IBS 
patients from the cohort initially examined five years before and described 
previously, were examined in detail. This was done in the general practitioners 
surgery by a single investigator with the consent of the GP. 
Selection of this small cohort of patients was on the basis of the geographical 
location of the practice. Only those within two miles of the hospital were 
included. This restricted the practices to an urban area well served by public 
transport ; it was thought unlikely that transport considerations would be a 
notable determinant of reporting / attending / referring behaviour within this 
area. The patients were drawn from 16 general practices. 
The descriptions from the medical records were then compared with those 
obtained from the postal questionnaire and from the initial assessment five 
years previously. Each record was examined in full, noting the number of 
consultations, the formulations of the GP, any prescribed treatment, and any 
other recorded comments (particularly if they related to emotional or 
psychological factors, or to specific life events). The index consultation was 
held to be that of the specialist gastrointestinal clinic. 
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Consultations were classified according to the principal (first, bold, or 
underlined) complaint, symptom, or diagnosis. 
Gastrointestinal consultations were those in which abdominal pain, bowel 
habit, dyspepsia, nausea, bloating, fullness, or defaecatory difficulty were 
predominant. The remaining consultations were classified other. Although this 
is a somewhat artificial division, particularly given that IBS sufferers often 
complain of nongastrointestinal symptoms, I wished to examine whether there 
was a change in this aspect of the presentation with clinic attendance. 
Depression and anxiety states were considered to have been diagnosed 
when they were a part, however minor, of the written record or formulation 
of the consultation. 
The characteristics of the 20 patients were similar to those of the whole 
group. [Table 52] However of those chosen for detailed examination of their 
GP notes, only three were in the self reported unchanged or worse category. 
This renders comparison between the general outcome groups all but 
impossible. In analysis of the 20 patient cohort the patients are not subdivided 
into outcome classes. 
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Results and Analysis 
Table 52. Subject characteristics. (mean) n = 20 
age (years) 
sex ratio ( f : m ) 
high fibre diet at five years 
symptom duration (months) 
initial anxiety score 
five year anxiety score 
initial depression score 






26 - 69 
14 : 6 








range 0 - 12 
3.4 
range 0 - 10 
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Results and Analysis 
One image of IBS patients commonly held by hospital -based doctors is of 
a patient frequently consulting their general practitioner with abdominal or 
indeed other complaints. However this was nor borne out by examination of 
the GP record cards. 
Table 53. Temporal relationship between index consultation 
and number of GP consultations. 
Time from index consultation. Number of consultations (mean, range) 
gastrointestinal nongastrointestinal 
60 - 12 months 5.1 2 - 31 2.0 0 - 18 
12 - 3 months 1.0 1 - 10 1.3 0 - 10 
3 months - index consultation 3.0 0 - 7 0.7 0 - 7 
index consultation - 3 months 0.7 0 - 2 0.3 0 - 2 
3- 12 months 2.5 0 -8 1.4 0 -5 
12 - 60 months 5.5 0 - 19 1.8 0 - 10 
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Results and Analysis 
Table 54. Time to GP reconsultation after index consultation 
Mean interval before range number not 
reconsultation consulting 
gastrointestinal complaint 5.4 months 1 - 18 3 
other complaints 6.5 months 4 - 12 5 
Five of the patients had had a previous diagnosis of IBS, four in the same GI 
clinic within the five year preindex consultation study period. The time interval 
to rereferral ranged from one to four years. Nine of the patients had had a 
diagnosis of 'dyspepsia' recorded. In three patients there were grounds for 
suspecting other somatisation reactions - two with 'psychogenic chest pain', 
one with 'nervous headache'. A specific life event was recorded as being 
significant for the consultation in five patients at index consultation or within 
the preceding three months (marital difficulties (2), engagement, housing, 
worry about employment). 
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Results and Analysis 
There was no consistent correlation between the frequency of consulting (for 
gastrointestinal or non -gastrointestinal complaints) and symptoms in the 
questionnaire. 
Likewise there was no clear relationship between GP consulting behaviour 
before and after the index consultation, and changes in the symptoms 
between the initial assessment and the five year postal questionnaire. 
The complex nature of the relationship between consultations and 'symptoms' 
was confirmed. Attendance at a gastrointestinal clinic, or some element in the 
consultation which prompted it, had very little discernable impact on the long 
term frequency with which IBS sufferers consulted, nor on the predominance 
of gastrointestinal complaints. There was an early reduction in the frequency 
of consultation but this was no longer evident after 12 months. 
Nonetheless most patients considered the clinic attendance to have been 
helpful - regretably I did not examine whether the general practitioners shared 
this view. Taken with the poor correlation between reported symptoms and 
overall subjective self- assessment, these findings emphasise the difficulty in 
establishing useful 'outcome measures' in outpatient management of IBS. 
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Results and Analysis 
Relationship with anxiety and depression 
Seven patients had a previous diagnosis of depression or anxiety and two 
patients had had both diagnostic labels accorded them. These comments 
were distributed almost evenly throughout the five year period ; median 25 
months, range 1 - 52 months. 
In the five years after index consultation and clinic diagnosis of irritable bowel 
syndrome, five patients were thought to have suffered anxiety or depression 
and one both. Only two of these patients had not previously been within one 
or other diagnostic category. 
Only two patients had received anti -depressant medication in the ten year 
period. A further four patients had received anxiolytics, exclusively diazepam. 
One patient had received propranolol for anxiety associated palpitations. 
Three patients had been referred to a psychiatric outpatient clinic in the five 
year follow -up period : diagnoses of personality disorder, depression (no 
antidepressant treatment), and alcohol dependancy were made. 
The high incidence of depression and anxiety, often not reported by the 
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patients themselves, was striking. Its timing seemed unrelated to the index 
consultation and to the duration of the IBS symptoms. 
I found no correlation between the pattern of consultation and either index 
or five year anxiety scores. [Tables 55,57] The index depression scores 
showed a weak correlation with gastrointestinal consulting rates though this 
was notable only for the period before the index consultation. [Table 56] The 
five year depression rates showed no such correlation. [Table 58] This is 
further evidence of an association between illness behaviour (GP consulting) 
and depression scores. 
Somewhat paradoxically the psychometric scores at index consultation were 
a poor guide to previous or subsequent psychiatric diagnosis with no 
significant difference between the groups of patients. [Tables 59,60] However 
the trend in each score was for the mean to be higher in those with a 
previous or subsequent diagnosis of depression / anxiety - perhaps with a 
greater number of patients this trend would have become a significant 
difference. 
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Results and Analysis 
Table 55. The relationship between GP consultation rates and 





60 - 3 months 0.21 0.31 -0.13 0.38 
3 months - index 0.15 0.24 -0.07 0.10 
index - 3 months 0.37 0.37 -0.50 -0.45 
3 - 60 months 0.20 0.17 -0.11 -0.03 
interval (months) -0.21 -0.12 0.06 0.15 
r = product- moment correlation coefficient not significant 
R = Spearman coefficient of rank correlation 
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Results and Analysis 
Table 56. The relationship between GP consultation rates and 
index depression scores. (n = 20) 
gastrointestinal nongastrointestinal 
r R r R 
60 - 3 months 0.75 " 0.54 0.12 0.50 
3 months - index 0.68 0.53 0.45 0.37 
index - 3 months 0.47 0.41 -0.16 -0.29 
3 - 60 months 0.20 0.17 0.18 0.21 
interval (months) 0.07 -0.04 0.04 -0.01 
r = product- moment correlation coefficient 
R = Spearman coefficient of rank correlation 
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** p < 0.01 
* p < 0.05 
Results and Analysis 
Table 57. The relationship between GP consultation rates and 
five year anxiety scores. (n = 20) 
gastrointestinal nongastrointestinal 
r R r R 
60 - 3 months 0.18 0.44 -0.22 -0.12 
3 months - index -0.14 -0.05 -0.46 -0.5 
index - 3 months 0.41 0.47 -0.46 -0.5 
3 - 60 months 0.06 0.00 -0.31 -0.42 
interval (months) 0.12 -0.08 0.30 0.40 
r = product- moment correlation coefficient 
R = Spearman coefficient of rank correlation 
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not significant 
Results and Analysis 
Table 58. The relationship between GP consultation rates and 
five year depression scores. 
gastrointestinal nongastrointestinal 
r R r R 
60 - 3 months 0.43 0.74 0.09 0.07 
3 months - index 0.11 0.22 -0.11 -0.16 
index - 3 months 0.06 0.06 -0.11 -0.16 
3 - 60 months 0.10 -0.14 -0.10 -0.25 
interval (months) 0.35 -0.29 -0.01 0.21 
r = product- moment correlation coefficient 
R = Spearman coefficient of rank correlation 
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Results and Analysis 
Table 59. Index depression and anxiety scores in those with previous 
depression I anxiety vs those without such a diagnosis. 
present absent 
mean SD mean SD p 
depression 5.4 2.3 4.6 3.5 0.34 
anxiety 9.7 2.1 7.1 4.9 0.68 
Table 60. Index depression and anxiety scores in those with subsequent 
depression I anxiety vs those without such a diagnosis. 
present absent 
mean SD mean SD p 
depression 6.0 3.0 4.8 3.1 0.57 




The Symptom Complex 
The difficulties in assessing the response to treatment in IBS are well 
illustrated by the poor correlation between the subjective general evaluation 
and the changes in subjective self- recorded symptom scores in the clinical 
trial. The symptomatic assessment was extensive but objective measures did 
not include measurement of stool weight nor enteric transit time. Although 
there is some suggestion that stool weight and transit time correlate with 
'diarrhoea' or 'constipation' (Eastwood et al 1984, Cann et al 1983), the 
balance of evidence is against a clear cut association (Soltoft et al 1981, 
Oettle and Heaton 1987). There is no correlation between such measures and 
self -reported symptoms such as abdominal pain and bloating in IBS patients 
(Hillman et al 1982). 
Nor did I study intestinal motility. The use of gastrointestinal motility 
investigations invests the process of investigation with a degree of invasion 
and potential morbidity which, though slight, must change the nature of the 
investigator- subject (doctor -patient) relationship. I wished to avoid this as far 
as possible in view of my putative contention that this relationship is itself an 
important element in the behaviour of IBS patients. There is no evidence that 
motility studies help in the treatment of individual patients, nor that changes 
with treatment are any guide to the efficacy of the treatment; nor indeed is 
there evidence even of consistent changes in IBS with treatment. Throughout 
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I have been concerned with aspects of assessment and management which 
might prove useful in the routine care of irritable bowel syndrome patients. 
Natural History 
The study confirms the relatively benign medium term prognosis for IBS 
patients. The diagnosis is a safe construct with few patients subsequently 
being accorded an alternative diagnosis or changes in symptom pattern 
which required review of the diagnosis. Nonetheless there is a substantial 
minority of IBS patients in whom the symptom complex is a persisting, 
troublesome feature of their lives. 
Fibre intake and fibre supplementation as treatment 
Pretreatment dietary fibre intake was, as expected, related to degree of 
constipation. In the clinical trial the pretreatment levels were certainly not 
significantly less than in the general population from whom the patients were 
drawn. The supplement of fibre represented a relatively small addition - 
perhaps a greater supplement would have had a greater effect. As it was the 
fibre tablets produced a similar change to that afforded by placebo. However 
it is a well tolerated treatment as witnessed by the large proportion of patients 
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continuing with this approach after 5 years. My analysis does not confirm an 
actual, continuing high fibre diet (or higher than at initial presentation) ; 
nonetheless that so many patients report this persisting change in lifestyle 
is surely significant. 
Biochemical Indices 
The indices I examined offered no prospect of differentiating IBS patients into 
subclasses which might have afforded insights into shape of the triangle in 
the proposed IBS model. Nor does it seem likely that they will afford useful 
diagnostic information. 
Psychopathology 
Many studies have confirmed the high prevalence of psychopathology in IBS 
patients. Despite this, formal psychometric assessment is rare in general and 
gastrointestinal clinics. Reliance on traditional clinical judgement is based in 
part on familiarity, in part on lack of time, and in part on suspicion 
(occasionally denigration), of psychological testing. I wished to obtain a 
reliable, rapid, user -friendly (for patient and doctor) insight into two possibly 
relevant psychological parameters; depression and anxiety. 
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The visual analogue scale was easily obtained, and a useful guide to possible 
psychopathological factors in IBS patients. The results further suggest that the 
VAS results may be of predictive value, perhaps able to identify those patients 
who will improve whatever treatment is exhibited. 
While in the clinical trial high depression scores seemed to be associated with 
poor symptomatic improvement (whether this be a true response or a 
placebo effect), in the five year follow -up cohort anxiety score at five years 
best differentiated between improved and unimproved groups. One frequently 
proferred explanation for the latter finding is that in unimproved patients 
continuing gastrointestinal symptoms fuel persistent anxiety. However, anxiety 
ratings were not increased over the intervening five years in those who were 
worse or unchanged, and the outcome groups were indistinguishable with 
respect to initial and five year gastrointestinal symptoms; their duration, 
pattern, or severity (with the single exception of abdominal pain). Patients who 
felt improved reported less pain and less anxiety at five year follow -up than 
their unimproved counterparts, but these differences did not reflect any other 
differences in symptomatology. 
An alternative explanation is that the sustained anxiety ratings and 
gastrointestinal symptomatology are both manifestations of a persisting, 
abnormal perception of stress and gastrointestinal experience in patients who 
do not improve. Such a hypothesis is supported by the similarity between the 
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outcome groups in terms of gastrointestinal symptoms and by the observed 
differences in anxiety ratings. 
Other than the duration of follow -up, the striking difference between the three 
month clinical trial subjects and those in the five year follow -up cohort was 
the duration of symptoms at initial assessment, reflecting the criteria for 
recruitment into the short-term therapeutic trial. It is conceivable that anxiety 
is more involved in the longterm maintenance of the IBS symptom complex, 
and changes in mood (especially depression) in determining shorter -term 
fluctuations in perceived distress and illness behaviour in response to life 
events against this background. Depressed affect would therefore have 
important implications for response in treatment trials of short duration, but 
personality traits determining perception of and response to anxiety might 
modulate the sustained tendency to express the IBS symptom complex as 
consulting behaviour. 
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General Practitioner Consultations 
The complex nature of the relationship between consultations and 'symptoms' 
was confirmed. Taken with the poor correlation between reported symptoms 
and overall subjective self- assessment these findings raise the question of just 
what should be useful 'outcome measures' in outpatient management of IBS. 
Conceivably the longer -term stability of the consulting behaviour goes hand 
in hand with with a true reduction in the frequency or severity in experience, 
or successful reattribution. The consulting behaviour persists as an element 
in the coping strategy which has now been bolstered by the outpatient clinic 
consultation. Alternatively the change may lie in the attitude of the general 
practitioner who no longer feels it nececessary to refer the patient on. 
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The Placebo Response 
The therapeutic trial confirms the substantial placebo effect which has been 
previously reported to operate during treatment of IBS patients. The placebo 
response has been defined as 
'a psychophysiological effect independent of 
pharmacological mechanisms' 
(Shapiro 1959 -60) 
Such a response need not, in general, be limited to subjective experience, 
though it is this aspect which is most apposite to the present study. Nor is 
deception a necessary part of the 'placebo response' (Brody 1982) though 
this too is of lesser consequence in the double blind situation. 
The nature of the placebo response has been the subject of much 
speculation but is is clear that the doctor -patient relationship is a critical 
component. Adler and Hammet (1973) discuss the importance of the placebo 
response within the context of various models of illness or distress. They 
emphasise the transcultural element of the process by which the sick role 
provides a socially sanctioned respite, and the practitioner (here the physician 
but elsewhere the healer, priest etc) a coherent, culturally meaningful 
explanation of the complaints. 
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These two elements are interactive ; the patients are helped by ; 
1. 
2. 
participation in a shared system that seeks to explain the 
apparently chaotic symptoms. 
access to a relationship with a culturally sanctioned figure who 
can offer an explanation for the symptoms and /or behaviour. 
The considerable placebo effect highlights the potential central importance 
of the doctor -patient relationship in the natural history of the IBS symptom 
complex. In this context it is noteworthy that the placebo effect seems to 
exert a disproportionately greater influence on the symptom domain of the 
global score, which seems to have greater import for the general sense of 
well -being than the experience of pain, or alterations in faecal frequency or 
consistency. 
Perhaps the patients are aware, or become reassured, that the change in 
bowel habit does not indicate serious underlying disease, but are less well (or 
less easily) reassured about the benign aetiology of the other symptoms. 
Bowel habit (its perception and reporting) may be more susceptible to the 
process of reassurance and reattribution than the other complaints. 
The therapeutic impact of the doctor -patient relationship might also underpin 
the continuing consulting behaviour of IBS patients. It may be particularly 
important in circumstances in which there is no specific treatment liable to 
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produce dramatic 'symptomatic' improvement. Thomas (1978) argues that 
patients may indeed tolerate situations in which no treatment is offered rather 
better than might be anticipated and that in some such patients find a 
directive, paternalistic consultation more effective than a sharing consultation 
style. IBS patients may be particularly disadvantaged by such a sharing 
approach to consultation : the sharing style may serve to perpetuate the 
mind - body dualism even though, somewhat paradoxically, it arises out of a 
concern to promote a holistic, non -paternalistic approach to the patients 
complaints. 
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Model of IBS 
Implications for management 
The model of IBS as a behavioural disorder, the characteristics of which are 
determined by input from three domains which can be considered the points 
of a triangle (Ford et al 1982), has proved useful. However by delineating the 
shape and identifying the apices (soma, psyche and circumstance) the model 
may detract from the essential dynamic nature of the interaction. The points 
are seen as fixed ; although the shape of the triangle can vary between 
individuals, and over time in a single individual. 
Clearly the psyche apex of the triangle has many inputs and it may be 
inappropriate to represent it as a single point. Particularly, the findings 
suggest that the inputs may vary in importance over time. The circumstance 
apex has proved extremely difficult to examine, and time -consuming 
examinations of life events are unlikely to gain widespread use in routine 
clinical practice. The influence of life events on illness behaviour in general 
and on the IBS symptom complex in particular has proved elusive. Ford et 
al (1987) suggested that life events operated by causing anxiety in patients 
who were suffering from a depressive mood disorder. 
The soma apex (perhaps best considered in our current understanding as the 
interaction of dietary constituents and enteric motility) has likewise proved 
difficult to examine. While the model recognises the input from each apex it 
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therefore remains difficult to determine the shape of the triangle in any 
individual patient at any given time. Further the behavioural, dynamic basis of 
the model is somewhat submerged in the two dimensional representation and 
the role of past experience and learning are under -represented. 
The onset of symptoms in this model of IBS has been explained in terms of 
Catastrophe Theory (CT). Developed by Thom, CT purports to predict the 
behaviour of dynamic systems by reference to a limited number of elementary 
catastrophe models (Stewart and Peregoy 1983). The models configuration 
is determined by the number of control factors, which are held to represent 
the topographic axes. 
Control factors influence events qualitatively, and independent of their 
interactions. The 'catastrophe' is a mathematical discontinuity at which point 
the system moves into another state. It is attractive to picture the discontinuity 
as the onset of symptoms necessitating medical treatment. However the 
model is a qualitative one - the axes imply no scale or degree, relative or 
absolute. It allows little, if any, inference to be drawn on the interactions of 
the factors, a limitation acknowledged by many proponents of CT. Further, 
while the change in state can be discontinuous (a catastrophe), an identical 
position can usually be reached in the model by a non -discontinuous route. 
CT has been suggested as a model for a wide range of behaviours. The 
mathematical basis has been criticised and although it allows elegant 
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topographical models to be invoked, CT does not help identify the number 
of aetiological factors, their relative importance, or the way in which they 
interact in IBS. Further the onset of irritable bowel symptoms is not a discrete 
event - the process can be seen as a flow through a series of boundaries - 
experience becomes symptom ; symptom produces consulting behaviour ; 
consulting behaviour prompts clinic referral. 
Nor does the model help predict the natural history or outcome of the 
symptom complex. Another disadvantages of CT is its perpetuation of the 
dualistic approach by which psychological states and motor behaviour are 
separated (they are often represented by diverging axes). 
The three domain model may continue to be helpful but it is prudent to 
consider each domain as the summation of several influences, and the 
domains themselves as inextricably intertwined. The model can be developed 
and refined by drawing from the developing discipline of psychobiology the 
central theme of rhythm or oscillation (Weiner 1989). Traditionally biological 
systems or functional units have been accorded a homeostatic character, by 
which the system seeks to preserve its steady state against external or 
indeed internal stressors. But the steady state belies an oscillating, rhythmic 
system. Such oscillations are inevitable in systems which depend on feedback 
loops for control and coordination of homeostatic and other functions. The 
feedback loops involve a time delay which are one source of the oscillation. 
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Many systems utilise signals which are themselves rhythmic. Such systems 
have intrinsic pacemakers by which the frequency, amplitude, and form of the 
oscillation can be established. A transition from the usual 'steady' state or 
mode is termed a bifurcation. The base rhythm and the change can be 
modelled mathematically using nonlinear differential equations (Garfinkel 
1983). Dysrhythmic dynamics (chaos) may be almost inevitable in some 
systems, in others chaotic oscillation may be an unpredictable consequence 
of external stressors. Chaotic function characterises a subsystem in disease 
or disorder. 
The characteristic feature by which IBS patients are recognised is their 
behaviour : the function of the system (patient) is paramount, rather than its 
structure. There are clearly rhythms of gastrointestinal motility, even though 
their relation to function is not yet well established. Likewise individual mood 
and emotional states seems to have an inherent rhythm, which have been 
of particular interest in psychological disorders (Wehr and Goodwin 1981, 
Vidacek et al 1988). Several of the influences in the IBS symptom complex 
can therefore be visualised as potentially rhythmic phenomena. The 
integration of these influences will produce the dynamic we see as behaviour. 
213 
It is not be necessary to postulate any major increase in (for example) stress 
or anxiety - a relatively small absolute change can be amplified by the 
oscillation(s) or could significantly modulate the overall dynamic. The time 
scale of the oscillations may likewise be critical - it may determine the 
frequency within the day or week with which the patient experiences any (or 
all) of the symptoms. The rhythm may change its ampitude or its frequency - 
it is interesting to speculate that the former might be true for mood or 
emotional state, the latter for gastrointestinal motility. Perhaps those people 
with generally high anxiety levels may respond to changes in circumstance 
with changes in depression or other inputs such that the system overall 
(physical and emotional) is dysequilibrated. High baseline levels may be 
more, or less, resistant to change. 
The illness behaviour of IBS can be seen as one aspect of the systems' 
strategy for establishing a satisfactory function in altered circumstances. 
Goldberg's reattribution may diminish the amplitude or the frequency of the 
anxiety or dis -ease engendered by the perceived experience. Perhaps this 
goes some way to explain the high incidence of placebo response and the 
reported success with such a wide range of treatment modalities - alterations 
to diet, hypnosis, behavioural therapy, biofeedback etc. The physician is part 
of the interaction - his behaviour may be subject to rhythmic changes too and 
he plays a part in the dynamic function of the system. Consultation with the 
physician is an integral part of the coping device (Tessler et al 1976). The 
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medical model, with its emphasis on structure, finds it difficult to accomodate 
this kind of approach. 
The complexity of the forces which forge and maintain the symptom complex 
and illness behaviour, and the potentially dramatic impact of what seems in 
isolation a slight change in one potential influence is also explained within this 
model. The effect of previous experience and learning, and of social and 
cultural influences are recognised. This model of irritable bowel syndrome can 
accomodate the heterogeneity of IBS patients and can incorporate most of 
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7 Day Diary 
Day 1 2 3 4 5 6 7 
number of daily 
bowel movements 
(0,1,2...) 
type of stool: 













DSSI (after Foulds and Bedford) 
Recently I have worried about every little thing. 
False True If true this has upset me: 
A bit A lot Unbearably 
Recently I have been so miserable that I have had 
difficulty with my sleep. 
False True If true, this has upset me: 
Unbearably A lot A bit 
Recently I have had breathlessness or a pounding of my heart. 
False True If true, this has upset me: 
A bit A lot Unbearably 
Recently I have been so worked up that I couldn't sit still. 
False True If true, this has upset me: 
Unbearably A lot A bit 
Recently I have been depressed without knowing why. 
False True If true, this has upset me: 
Fairly Very Extremely 
Recently I have gone to bed not caring if I woke up. 
False True If true, this has upset me: 
Desperately Very Fairly 
Recently, for no good reason, I have had feelings of panic. 
False True If true, this has upset me: 
A bit A lot Unbearably 
Recently I have been so low in spirits that I have sat for 
ages doing absolutely nothing. 
False True If true, this has upset me: 
Unbearably A lot A bit 
Recently I have had a pain or tense feeling in my head or neck. 
False True If true, this has upset me: 
A bit A lot Unbearably 
Recently the future has seemed hopeless. 
False True If true, how hopeless ? 
Completely Very A bit 
Recently worrying has kept me awake at night. 
False True If true, this has upset me: 
A bit A lot Unbearably 
Recently I have lost interest in just about everything. 
False True If true, how much loss ? 
Complete A lot A bit 
Recently I have been so anxious that I couldn't make up my mind about the simplest thing. 
False True If true, how anxious ? 
Fairly Very Extremely 
Recently I have been so depressed that I have thought of doing away with myself. 
False True If true, how seriously ? 
Complete Very Not very 
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Appendix 3 
Visual Analogue Scales 
This is a rather unusual way of trying to find out how you feel. Just to give you the idea 
I am going to try it out first on finding out how you feel about warm weather. People differ 
from each other in how they feel about warm weather. Some like it very much. Others can't 
stand it. Most people of course are somewhere between the two. 
Underneath some statements have been placed along a line. I want you to put a mark on 
the line to show me how you feel about warm weather. You don't have to put it opposite 
a statement if you don't want to ; you can put your mark anywhere along the line in 
between statements if you like. 
Weather 
I dislike warm weather 
I like it to be fairly warm 
I like the weather to be 
pretty hot 
I like it best when there 
is a sizzling heat wave 
On the next page are two more lines with statements on them, this time about feelings. 
People often vary in how they feel, so when you are deciding how to mark each line, think 
about how you personally have been feeling over during the past month. 
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Remember. Think about 
how you have been feeling 
during this past month 
Anxiety 
I never worry about anything 
I get a bit worried occasionally 
I often get worried about things 
I tend to worry a great deal 
I am always in a state of terrible 
worry and anxiety 
Depression 
I never feel unhappy 
I sometimes feel a bit unhappy 
I am quite often in low spirits 
I frequently feel very miserable 




How many bowel movements do you usually 
have per day or per week ? 
Do you have to rush to the toilet to 
open your bowels ? 
Are your motions ever like dry pellets 
or thin strips ? 
0 never 
1 occasionally 
2 most months 
3 most weeks 
4 most days 
0 never 
1 occasionally 
2 most months 
3 most weeks 
4 most days 
Are you motions ever watery or unformed ? 
0 never 
1 occasionally 
2 most months 
3 most weeks 
4 most days 
Do you ever have to strain during a 
bowel motion ? 
Do you ever feel the bowel is not 
quite empty after a bowel motion ? 
0 never 
1 occasionally 
2 most months 
3 most weeks 
4 most days 
0 never 
1 occasionally 
2 most months 
3 most weeks 
4 most days 
Do you ever experience pain in the tummy ? 
(that is not your monthly period). 
0 never 
1 occasionally 
2 most months 
3 most weeks 
4 most days 
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Is the tummy pain changed by passing wind 




Does the tummy pain coincide with a change 
in the shape, consistency or frequency 




Is the tummy pain affected by what you eat ? 
0 no 
1 yes 
If so can you describe how ? 
Do you make a conscious effort to eat a 
diet high in roughage (fibre) ? 
0 no 
1 yes 
Do you ever feel that worry or nerves upset 




Do you ever see your GP because of trouble 





Do you use laxatives or purgatives ? 
0 never 
1 occasionally 
2 most months 
3 most weeks 
4 most days 
Do you use any medications prescribed by your 
doctor for your tummy complaint ? 
If so what ? 
0 never 
1 occasionally 
2 most months 
3 most weeks 
4 most days 
Have you tried any other method of 
helping your tummy complaint ? 
(eg herbalism, acupuncture, hypnosis ...) 
0 no 
1 yes 
If so what ? 
Did it help ? 
Since you were seen at the Western General 
Hospital, have you attended any other clinic 
with a similar problem ? 
Do you think your attendance at the 
Western General Hospital was helpful ? 
0 no 
1 one 







Do you ever feel upset for no obvious reason ? 
Do you have an unreasonable fear of being in 
enclosed spaces such as shops, lifts etc ? 
Can you think as quickly as you used to ? 
Have you felt as though you might faint ? 
Do you find yourself worrying about getting 
some incurable disease ? 
Do you feel that life is too much effort ? 
Do you feel uneasy and restless ? 
Do you regret much of your past behaviour ? 
Do you sometimes feel really panicky ? 
Do you feel uneasy about travelling on buses or 
the underground even if it is not crowded ? 
Do you wake early in the morning ? 
































not at all 
Do you dislike going out alone ? 
Do you experience long periods of sadness ? 
Do you often feel 'strung up' inside ? 
Do you worry unduly when relatives are late 
coming home ? 
Do you have to make a special effort to face up 
to a crisis or difficulty ? 
Have you ever had the feeling that you are 
'going to pieces' ? 
Are you scared of heights ? 
Do you find yourself needing to cry ? 
Do you have bad dreams which upset you 
when you wake up ? 
Do you feel panicky in crowds ? 
Have you lost your ability to feel sympathy 











very much so 
sometimes 


















Platelet serotonin assay 
Methodology 
Whole blood is taken from the antecubital vein with the patient seated rested. It is added 
immediately to anticoagulant in a 10m1 plain polystyrene tube and spun at room 
temperature for 10 min at 121 G. The upper two thirds of the platelet rich blood is 
harvested. Two aliquots are kept ; one for platelet count and one for platelet serotonin. 
The remaining plasma is then diluted with Krebs Saline and aliquots of the remainder are 
preincubated with saline or saline with chlorimipramine to measure passive diffusion. 
These aliquots are then added do varying concentrations of serotonin in saline, spiked with 
titritiated serotonin and incubated for one minute at 37 °C. 
Uptake is stopped by the addition of ice cold chlorimipramine in saline and the tubes spun 
for 90s at 4000G and 4 °C. The supernatants are aspirated, the pellet digested with ammonia 
solution for 40 minutes, and the aliquot counted. 
For platelet serotonin 100 ul of the internal standard for recovery is added to the platelet 
rich plasma which is incubated for 40 min at 37 °C and then frozen at -20 °C. The plasma 
is then thawed, 100 ul perchloric acid /cysteine solution is added and left at 4 °C for 15 
minutes. The deproteininsed plasma is then spun at 4 °C and 100000G for 15 min. The 





Have you ever felt you should cut down your drinking ? 
Have people annoyed you by criticizing your drinking ? 
Have you ever felt bad or guilty about your drinking ? 
Have you ever had a drink first thing in the morning to 
steady your nerves or get rid of a hang -over (eye- opener) ? 
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